# SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED)

## I. <u>GENERAL INFORMATION</u>

ſ

Device Generic Name:

Device Trade Name:

Applicant's Name and Address:

Date of Panel Recommendation:

Premarket Application (PMA) Number:

Date of FDA Notice of Approval:

Expedited:

Implantable Middle Ear Hearing Device

Esteem® ,consisting of: Sound Processor Model 2001 Sensor Model 7002 Driver Model 7502 Esteem Programmer Model 6001 Personal Programmer Model 8001 Intraoperative System Analyzer Model 3001 Accessories

Envoy Medical Corporation 5000 Township Parkway St. Paul, MN 55110

December 18, 2009

P090018

March 17, 2010

Granted expedited review status on August 27, 2009 because the Esteem® represents a breakthrough technology which provides an alternative to non-implantable and partially implantable hearing aid technology.

## II. <u>INDICATIONS FOR USE</u>

The Esteem is intended to alleviate hearing loss in patients by replicating the ossicular chain and providing additional gain. The Esteem is indicated for patients with hearing loss that meet the following criteria:

- 18 years of age or older
- Stable bilateral sensorineural hearing loss
- Moderate to severe sensorineural hearing loss defined by Pure Tone Average (PTA)
- Unaided speech discrimination test score greater than or equal to 40%
- Normally functioning Eustachian tube
- Normal middle ear anatomy
- Normal tympanic membrane
- Adequate space for Esteem implant determined via high resolution CT scan
- Minimum 30 days of experience with appropriately fit hearing aids.

PMA P090018: FDA Summary of Safety and Effectiveness Data

## III. <u>CONTRAINDICATIONS</u>

*Esteem*® is contraindicated under the following conditions:

- History of post-adolescent chronic middle ear infections, inner ear disorders or recurring vertigo requiring treatment, disorders such as mastoiditis, Hydrops or Meniere's syndrome or disease
- Known history of fluctuating air conduction and/or bone conduction hearing loss over the past one year period of 15 dB in either direction at 2 or more frequencies (from 500 to 4000 Hz)
- History of otitis externa or eczema for the outer ear canal
- Cholesteatoma or destructive middle ear disease
- Retrocochlear or central auditory disorders
- Disabling tinnitus, defined as tinnitus which requires treatment
- History of keloid formation
- Hypersensitivity to silicone rubber, polyurethane, stainless steel, titanium and/or gold
- A pre-existing medical condition or undergoing a treatment that may affect healing process
- During pregnancy

## IV. WARNINGS AND PRECAUTIONS

The warnings and precautions can be found in the Esteem® labeling.

## V. <u>DEVICE DESCRIPTION</u>

1

The Esteem is a totally implantable middle ear hearing device. The Esteem consists of three implantable components, the Sound Processor, the Sensor and the Driver, and external instruments for interrogating, testing and programming the Esteem. Specifically, the Esteem includes the Model 2001 Sound Processor, Sensor Model 7002, Driver Model 7502, Esteem Programmer Model 6001 with Esteem Programmer Software and Wand, Personal Programmer Model 8001, Intraoperative System Analyzer Model 3001, and accessories.

#### Implantable Components:

1. Sensor: The piezoelectric Sensor tip is attached to the incus bone. The Sensor senses vibrations from the tympanic membrane and malleus/incus and converts these mechanical vibrations into electrical signals that are sent to the Sound Processor (Fig. 1).

2. Sound Processor: The Sound Processor, which is implanted in the temporal bone and connected to the Sensor and Driver via leads, receives the electrical signal from the Sensor, amplifies and filters the signal to compensate for the patient's hearing loss profile. The enhanced signal is then sent to the Driver (Fig. 1).

3. Driver: The piezoelectric Driver tip is attached to the stapes/incus bone. The Driver converts the enhanced electrical signal received from the Sound Processor back to

PMA P090018: FDA Summary of Safety and Effectiveness Data

page 2

mechanical energy, i. e. vibrations. The vibrations are transferred to the stapes and delivered as sound waves in the cochlea (Fig. 1).




Figure 1. Implantable Esteem components.

### External Instruments:

1. Esteem Programmer: This portable computer with the Esteem Programmer Software and a bi-directional telemetry wand is used to interrogate the implanted Sound Processor and to program it to a custom prescription for each patient.

2. Personal Programmer: This remote control device is used by the patient to adjust the volume and select pre-programmed settings in the Sound Processor.

3. Intraoperative System Analyzer: The ISA is a test system, consisting of a computer, software, Patient Interface Device and cables, used to verify the function of the implantable components during the implant procedure.

#### Accessories:

1. Unique Accessories: Several unique accessories are used during the implantation of the Esteem. The Glasscock Stabilizer is a sterile temporary retainer used to position and stabilize the Sensor and Driver during implant. The Replica Sound Processor is a tool used by the implanting physician to assess the space and placement requirements for the implantable Sound Processor. EnvoyCem is cement used to bond the Sensor and Driver

PMA P090018: FDA Summary of Safety and Effectiveness Data

page 3

tips to the ossicular chain. MedCem is bone cement used to anchor the Sensor and Driver to the mastoid floor during implant.

2. Standard Surgical Accessories: The surgical team may use several commercially available accessories that are either FDA cleared or exempt during the implant of the Esteem. These include bone screws, screwdriver, pliers, pick, syringes and sterilization tray.

Please refer to the Operator's Manual for additional details.

## VI. <u>ALTERNATIVE PRACTICES AND PROCEDURES</u>

There are several other alternatives for the correction of hearing loss. Each alternative has its own advantages and disadvantages. A patient should fully discuss these alternatives with his/her physician to select the method that best meets expectations and lifestyle.

Alternate practices and procedures include acoustic hearing aids and semi-implantable middle ear hearing devices. Hearing aids can be worn in a variety of configurations, including behind the ear, in the ear, in the canal or completely in the ear canal. Semi-implantable middle ear hearing devices typically consist of a middle ear implant and an external sound processing unit worn in and/or behind the ear.

## VII. MARKETING HISTORY

( ^

(

The Esteem received CE Mark certification approval May 3, 2006. Since market introduction, Envoy Medical has distributed approximately 85-100 Esteem devices throughout the European Union and Switzerland. In addition, approximately 20 Esteem devices have been distributed in India, Iran and Brazil since introduction in early 2008. The Esteem was also granted a Canadian License in March 2008 but no Esteem devices have been distributed to date. The Esteem has not been withdrawn from any market for any reason related to safety or effectiveness.

## VIII. POTENTIAL ADVERSE EFFECTS OF THE DEVICE ON HEALTH

Below is a list of the potential adverse effects (e.g., complications) associated with the use of the device.

Surgery of the middle ear to implant the Esteem involves manipulation and dissection of the ossicular chain (incus, malleus, and stapes) and exposes the inner ear to the risk of surgical trauma. Serious complications may occur during or after the surgery that may include, but are not limited to:

- loss in residual hearing due to surgical trauma
- device displacement after surgery,
- tissue buildup causing feedback or limited benefit
- device failure

• infection after surgery.

Additional complications include:

- swelling
- numbness and discomfort around the ear after surgery
- facial paralysis/paresis
- taste disturbance
- numbness of the tongue and face

For the specific adverse events that occurred in the clinical studies, please see Section X.

l

## IX. <u>SUMMARY OF PRECLINICAL STUDIES</u>

#### A. <u>Laboratory Studies</u>

#### **Biocompatibility**

Biocompatibility testing was conducted on all body contacting materials prepared to represent the finished device, as it would be implanted in the patient. All toxicity endpoints recommended for evaluation by ISO 10993-1: 2003 Biological Evaluation of Medical and Dental Materials and Devices, Part 1: Guidance on Selection of Tests and FDA Blue Book memorandum G95-1 were addressed. Tests conducted fall into the ISO guidance category for permanent (>30 days) implantable, bone and tissue contacting devices. In addition, all materials used in the implant accessory devices were subjected to tests in accordance to the ISO Guidance category for implant devices contacting tissue/bone for a limited (<24 hours) duration. All results for cytotoxicity, sensitization, implantation, chronic/acute toxicity and carcinogenicity were acceptable.

Implanted System Assemblies/Materials - Permanent Exposure (>30 Days)

	Test Method	Results
Cytotoxicity – L929 MEM Elution	According to ISO 10993-5; The "in-vitro" biological reactivity of the L929 mouse fibroblast cell culture is determined in response to an extract of the test material. The cells are allowed to grow to sub-confluency in tissue culture plates. An extract of the test material is prepared in Minimum Essential Media (MEM), which is transferred onto the cell layer. The plates are incubated for forty-eight hours at 37°C in a 5% Co <sub>2</sub> incubator, and scored for reactivity at twenty-four and forty-eight hours.	The test article is considered non-cytotoxic and meets the requirements of ISO 10993-5 guidelines.

Test	Test Method	Results
Sensitization - Klingman Maximization	According to ISO 10993-10; The test article will be exposed through test article extracts. Extracts of the test material are prepared in a (cotton seed oil) solution. The test begins with intradermal injections of Freund's Complete Adjuvant (FCA) and the test article. Seven days later the injection sites are covered with the test article or extract for a period of forty-eight hours. Fourteen days later a virgin site is challenged with a topical application of the test article or extract and scored at forty-eight hours.	Grade 1 reaction. A Grade 1 sensitization rate is not considered significant and the test article meets the requirements of the ISO 10993-10 guidelines.
Irritation - Intracutaneous Injection	According to ISO 10993-10; The test article will be exposed through test article extracts. Extracts of the test material are prepared in a (cotton seed oil) solution. A minimum of two rabbits are injected intracutaneously with the test article and control materials. The injected sites are examined over a seventy-two hour period for evidence of tissue reaction such as erythema, edema, and necrosis. Observations are scored according to the Classification System for Scoring Skin Reactions (Draize scale).	The test article is considered a negligible irritant and meets the requirements of ISO 10993-10 guidelines
Acute Systemic Toxicity-Systemic Injection Test	According to ISO 10993-10; Mice are injected systemically with extracts of the test article in standard solutions (normal saline and cottonseed oil). The animals are observed for signs of toxicity immediately after injection and at 4, 24, 48 and 72 hours post injection. The requirements of the test are met if none of the animals treated with the test article extract have a significantly greater adverse reaction the animals treated with the vehicle control.	This test found no systemic toxicity and meets the requirements of ISO 10993-11 guidelines.
Genotoxicity - Bacterial Reverse Mutation Assay	According to ISO 10993-3; The in-vitro assay is performed using Salmonella typhimurium to detect reverse mutations in histidine gene in a histidine- requiring strain to produce histidine-independence. Bacteria are plated onto histidine free medium and the plate is exposed to the test article extract. The plate is incubated and observed for growth after exposure. If the extract is showing mutagenic properties, reverse- mutated bacteria will now be able to grow on histidine free medium. The number of colonies is directly proportional to the mutagen potency.	The test article is considered non- mutagenic and meets the requirements of ISO 10993-3 guidelines.

(

1

(

PMA P090018: FDA Summary of Safety and Effectiveness Data

ł

page 6

 $\mathcal{N}$ 

Test	Test Method	Results
Genotoxicity -	According to ISO 10993-3; The test article is	The test
Mouse	administered in vitro, through a solvent compatible	article is
Lymphoma Assay	with the test system. At least 200 metaphase cells will	considered
	be analyzed for each test article extract and negative	non-
	control.	mutagenic
2	· .	and meets
		the
		requirements
		of ISO
		10993-3
	· · · · · · · · · · · · · · · · · · ·	guidelines.
Genotoxicity –	According to ISO 10993-3; The in-vivo assay is	The test
DNA-Effects-	performed by exposing the bone marrow of mice to	article is
Rodent	the test article extract. The bone marrow is collected	considered
Micronucleus	at predetermined harvest times (24 and 48 hours after	non-
Assay	treatment). Bone marrow smears are prepared and	mutagenic
	analyzed for the presence of micronuclei.	and meets
		the
	/	requirements
		of ISO
		10993-3
Implontation		guidelines.
Implantation -	According to ISO 10993-6, Test and control material is	The test
Short and Long Term	implanted into the paravertebral muscle (for	article is
reim	Intramuscular implants) of each of three rabbits. At the	considered a
	end of the observation period, the area of the tissue	non-irritant
	surrounding the center position of each implant strip	and meets
	will be examined macroscopically. Following gross	the
	observations, a veterinary pathologist will process the	requirements
	implanted sites for histopathologic evaluation.	of ISO
	Inflammation, fibrosis, hemorrhagic and necrosis are	10993-6
	evaluated on a scale and compared to the control article sites.	guidelines.
	Short Term = 2 weeks	
	Long Term = 12 weeks	
		· · · · · · · · · ·

( ·

í

(

Tissue/Bone Contacting Accessories/Materials - Limited Exposure (<24 hours)

Test 🕂 😳 🔧	Test Method	Results
Cytotoxicity – L929 MEM Elution	According to ISO 10993-5; The "in-vitro" biological reactivity of the L929 mouse fibroblast cell culture is determined in response to an extract of the test material. The cells are allowed to grow to sub- confluency in tissue culture plates. An extract of the test material is prepared in Minimum Essential Media (MEM), which is transferred onto the cell layer. The	The test article is considered non-cytotoxic and meets the requirements
	plates are incubated for forty-eight hours at 37°C in a 5% Co <sub>2</sub> incubator, and scored for reactivity at twenty-four and forty-eight hours.	of ISO 10993-5 guidelines

PMA P090018: FDA Summary of Safety and Effectiveness Data

,

Test	Test Method	Results
Sensitization -	According to ISO 10993-10; The test article will be	Grade 1
Klingman	exposed through test article extracts. Extracts of the	reaction.
Maximization	test material are prepared in a (cotton seed oil)	1
indominization:	solution. The test begins with intradermal injections	A Grade 1
	of Freund's Complete Adjuvant (FCA) and the test	sensitization
	article. Seven days later the injection sites are	rate is not
	covered with the test article or extract for a period of	considered
	forty-eight hours. Fourteen days later a virgin site is	significant
	challenged with a topical application of the test article	and the test
	or extract and scored at forty-eight hours.	article meets
	or extract and scored at forty-eight hours.	the
		requirements
		of the ISO
		10993-10
Irritation -	According to ISO 10993-10; The test article will be	guidelines.
Intracutaneous	exposed through test article extracts. Extracts of the	The test
Reactivity	test material are prepared in a (cotton seed oil)	article is
Redenvity	solution. A minimum of two rabbits are injected	considered a
	intracutaneously with the test article and control	negligible
	materials. The injected sites are examined over a	irritant and
	seventy-two hour period for evidence of tissue	meets the
	reaction such as erythema, edema, and necrosis.	requirements of ISO
,	Observations are scored according to the	
	Classification System for Scoring Skin Reactions	10993-10
	(Draize scale).	guidelines
Acute Systemic	According to ISO 10993-10; Mice are injected	This test
Toxicity-Systemic	systemically with extracts of the test article in standard	found no
Injection Test	solutions (normal saline and cottonseed oil). The	systemic
	animals are observed for signs of toxicity immediately	toxicity and
	after injection and at 4, 24, 48 and 72 hours post	meets the
1	injection. The requirements of the test are met if none	requirements
	of the animals treated with the test article extract have	of ISO
	a significantly greater adverse reaction the animals	10993-11
	treated with the vehicle control.	guidelines.
L		guidennes.

ť

(

PMA P090018: FDA Summary of Safety and Effectiveness Data

page 8

## **Electrical Testing**

É.,

 $(\cdot \cdot$ 

Extensive testing was conducted on the Esteem to verify the design criteria and device performance with respect to the electrical properties and specifications in support of its safety and effectiveness.

1. Implantable Components:

Test	Requirement	Results
Lead Continuity	Non-hermetic electrical connections between	Passed
Resistance	implanted system components shall have a combined	
	series resistance of less than 50 ohms.	
Lead Isolation	Non-hermetic electrical connections between	Passed
Resistance	implanted system components shall maintain a	
	minimum isolation resistance of at least 5 mega-	
	ohms.	
Harmonic	The device shall exhibit less than 10% harmonic	Passed
Distortion	distortion for nominal signals as tested per ANSI	
	S3.22 1996	
Input Noise	Total input-referred rms noise shall be less than 25 dB	Passed
	SPL over the range 200 Hz to 8000 Hz	
Volume Control	Volume shall be programmable over at least a 21 dB	Passed
	range.	
Programmable	Maximum output level shall be programmable over at	Passed
Output Limiting	least a 12 dB range.	
Confirmation	The implanted system shall output a confirmation tone	Passed
Tone	after a valid communication from the external	
	programmer.	
Implanted Battery	The implanted battery life shall be at least 5.0 years of	Passed
Longevity	typical operation, including a 1.0 year shelf life.	
BERI to EOL	The device shall continue to function for 14 days of	Passed
Operation	typical operation after initial Battery Elective	
	Replacement Indicator (BERI)	
Heat Generation	In normal operation or any single fault condition, no	Passed
	outer surface of the device shall be more than 2°C	
	above surrounding tissue temperature at 37°C.	
Implant	In electromagnetic environments (EN 60601-1-2 or	Passed
Electromagnetic	ANSI/AAMI PC69) the implanted components of the	
Sensitivity	system shall not generate an output exceeding an	
	equivalent input audio level of 85 dB SPL at 1kHz.	
Implant	In electromagnetic environments (EN 60601-1-2 or	Passed
Electromagnetic	ANSI/AAMI PC69) the implanted components of the	
Data Integrity	system shall maintain internally stored data.	
Electrostatic	When subject to ESD exposure according to IEC	Passed
Discharge	60601-1-2 Section 36.202.2, the implanted device	
	shall exhibit no loss of internally stored data and no	
	operational change.	
Identification	The implanted device shall store a unique serial	Passed
	number that can be interrogated by telemetry.	

PMA P090018: FDA Summary of Safety and Effectiveness Data

## 2. External Components:

t

Test 🐘 🚽 🔬	Requirement	Results
Electrostatic Discharge	After ESD exposure according to IEC 60601-1-2 and EN 45502-1, external components of the system will operate within normal limits.	Passed
Radiated Emissions	External components of the system shall not transmit electromagnetic fields at levels above 30.0 dBuV/m in the range 30 – 230 MHz or above 37.0 dBuV/m in the range 230 – 1000 MHz.	Passed
Radiated Immunity	The system shall provide means for ensuring integrity of transmissions between implant and external components in a 3 V/m electromagnetic environment over the range 80 MHz to 2.7 GHz.	Passed

## Mechanical Testing

Extensive testing was conducted on the Esteem to verify the design criteria and device performance with respect to the mechanical properties and specifications in support of its safety and effectiveness.

1. Implantable Components:

Test ₩	Requirement	Results
Lead Flex	Transducer leads to maintain continuity of 10 $\Omega$ or less following 82,000 flexural cycles at ±45° deflection.	Passed
Hermeticity validation	Transducer & Sound Processors to be Hermetic to 1x10-8 atm cm3/s when tested per MIL-STD-883 and Validated Internal Test Methods	Passed
Implantable components Shock and vibration	Implantable components in final packaging of to endure multiple drop sequences, implanted devices without packaging to endure vibration regimens per: EN 45502-1; 23.2.	Passed
Packaging testing	Final Packaging to Endure simulated distribution- shipping conditions per ASTM D4169.	Passed
Implantable components Operating and Storage Temperature	Implantable components to endure Storage Conditions of 0°C to 50°C and absolute humidity < 20 g/m3, and demonstrate operation in 35°C to 40°C with 30% to 100% Relative Humidity per EN 45502-1.	Passed

## 2. External Components:

Test	Requirement	Results
Personal	Personal Programmer to endure multiple drop	Passed
Programmer	sequences and vibration regimens 5-150 Hz 0.1	
Shock &	g2/Hz EN 45502-1; 23.1.	
Vibration Testing		

Test 🤉 🐳 🖉 🚽	Requirement	Results
Personal Programmer	Personal Programmer to endure Storage Conditions of -20°C to 60°C with and Relative Humidity from 15%	Passed
Operating and	to 95%, and demonstrate operation in 10°C to 30°C	
Storage Conditions	and Relative Humidity from 15% to 95%, as well as Absolute pressures spanning 700 hPa and 1060 hPa.	
	per EN 45502-1.	
Esteem Programmer Operating Conditions	Esteem Programmer to demonstrate operation in 10°C to 30°C with Relative Humidity of 20% to 80%, non-condensing.	Passed
Personal Programmer Spill-proof	Personal Programmer to demonstrate ability to endure a liquid spill, a drying sequence, and a 1 minute 2500 VDC over-voltage exposure, and remain functional.	Passed

## Life Testing

U S

(

A series of *in vitro* life test studies were conducted on the Sensor and the Driver transducers, the Sound Processor, and the System as a whole under accelerated conditions to evaluate potential failure mechanisms. In addition, shelf life testing under accelerated and real-time conditions was conducted on sterile product in the final packaging configuration.

-Test	Requirement	Results
Transducer Mechanical Reliability	Transducers subjected to 37°C environment with accelerated actuation signal for failures associated with mechanical fatigue. Test must demonstrate 8-year reliable life with 90% reliability and 90% confidence.	Passed
Transducer Environmental Reliability	Transducers subjected to elevated temperature/humidity/salinity environment with a typical drive signal providing a 16x Acceleration Factor for failures associated with exposure to the implanted environment. Test must demonstrate 8- year reliable life with 90% reliability and 90% confidence.	Passed
Sound Processor Battery Life	Sound Processors must demonstrate that following Shelf-life, the longevity must be at least 4.0 years, 5.5 years, and 2.0 year of operation before reaching BERI for continuous use, typical use, and worst-case use conditions, respectively.	Passed & Exceeded

## Shelf Life Testing:

(

(

Accelerated and real time shelf life testing was conducted to validate a 2-year shelf life for all EtO sterilized components. For the Gamma sterilized EnvoyCem, accelerated shelf life testing was conducted to validate a 3-year shelf life.

	Requirement	Results 🦉 🔍
Accelerated shelf	Packaging to demonstrate barrier integrity following	Passed
life – Packaging	Maximum EtO Sterilization, Expanded Range	
& Devices	Temperature Storage Conditions (the Age	
	Accelerating Factor), and	
	ASTM D4169 – Distribution Cycle 13.	
	Barrier Integrity verified with Visual Inspection, Dye Penetration, & Seal Strength	
	Devices to remain functional.	
Real time shelf life – Packaging & Devices	Packaging to demonstrate barrier integrity following 2- year Real Time Testing in compliance with ISO 11607. Requiring packaging to satisfy requirements for:	Passed
	Visual Inspection, Dye Penetration, Seal Strength.	

*Temporal Bone Testing*: Temporal bone model was used to validate system performance.

Test	Requirement	Results
Implanted System Output Capability	The implanted system shall be capable of generating stapes displacement of at least 100 nm p-p over the range 500 Hz to 2000 Hz in a typical temporal bone model.	Passed
Output Limiting	The system shall be capable of limiting the maximum output displacement over at least a 20 dB range to accommodate patient physiology differences of efficacy and safety.	Passed
Programmable System Gain Range	The system shall have a typical unaided vs. aided stapes displacement gain programmable over at least the range 0 dB to 40 dB for frequencies between 500 Hz and 2000 Hz in a typical temporal bone model.	Passed

### Software Verification/Validation

(

(

The Esteem Programmer, the Personal Programmer and the Intraoperative System Analyzer (ISA) contain software.

Off-the-shelf software is used for the operating system for the Esteem Programmer and ISA. Software development was conducted in conformance to FDA Guidance for Industry on Off-The-Shelf Software Use in Medical Devices (1999). Level of concern for the software used in the Esteem instrument components is minor, based upon the FDA Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices (2005).

Test 🔄 🗧 🧨 🖓	Requirement	Results
ISA Software	When used according to the labeling, the ISA software shall properly execute intraoperative measurements and display results.	Passed
Personal Programmer Firmware	When used according to the labeling, the Personal Programmer software shall properly communicate with the implanted device and provide visual indicators for the patient.	Passed
Esteem Programmer Software	When used according to the labeling, the Esteem Programmer software shall properly communicate with the implanted device, provide visual indicators for the clinician, and store programming information.	Passed

## **Conclusions of Preclinical Studies**

The results of the Preclinical studies provided reasonable assurance that the Esteem system was safe for clinical studies and implantation in humans for its intended use.

### B. Animal Studies

Early in the development of the Esteem, animal studies were conducted to research and evaluate the performance of the system. Prototype sensors were mounted in the middle ear of three chinchillas and followed for up to 98 days. Serial tympanometry and sensor voltage measurements were performed at three-week intervals. Results indicated that the chinchilla is a suitable model for long-term sensor implantation. The sensors appeared stable over time and frequency bandwidth. Histopathology showed no difference between the implanted ears and the controls. In order to verify the hermeticity and functionality of the Esteem under in vivo conditions, an animal implant study using a sheep was conducted. Four (4) Esteem devices, including Sound Processor, Sensor and Driver, were implanted in the back area of a sheep. Two (2) systems were explanted after 12 weeks and two (2) systems were explanted after 1 year. All systems were visually inspected and functionally tested after cleaning. There were no signs of corrosion or leakage noted; all functional testing indicated that the product performance was not affected by the in vivo implant conditions.

18

## X. <u>SUMMARY OF PRIMARY CLINICAL STUDIES</u>

The applicant performed a clinical study to establish a reasonable assurance of safety and effectiveness of the Esteem® device for alleviating hearing loss in subjects 18 years and older in the US under IDE # G070162. Data from this clinical study were the basis for the PMA approval decision. Additionally, the applicant performed an earlier clinical study (G000321) with the Esteem®. Although the PMA approval decision is based on G070162 alone, a description of both studies is given below.

#### Study Description (G070162)

In PMA submission P090018, the applicant presents data from a pivotal trial (IDE G070162) aimed at demonstrating the safety and effectiveness of the Esteem® system in subjects who have mild to severe hearing loss. This pivotal trial was designed as a prospective, multi-center, nonrandomized, clinical trial. Each of the 57 subjects implanted acted as both the test subject and the control by comparing his/her audiological test results and other measures prior to implant (under both unaided and aided conditions) to results at various time points after implantation.

#### <u>Regulatory History</u>

An earlier version of the Esteem® system was studied under a separate IDE (G000321). In the G000321 study, 72 total subjects were implanted at 6 investigational sites. Enrollment in this IDE has concluded. A number of G000321 subjects are now past their 3 and 4 year follow-ups. A high rate of failures (requiring 25 revision surgeries) was observed in this study, mainly due to inadequate bonding at the driver-stapes interface (17 events).

The current Esteem® system was studied under the IDE G070162. In order to address the high rate of failures observed in G000321, "Best Practices" (BP) for cleaning and drying was developed and used in the G000321 clinical post-BP subjects. In addition to the BP steps, a new 2-step EnvoyCem attachment procedure for the Driver and improved ISA testing are unique improvements to device implantation in the G070162 study. In this study, 57 subjects were implanted at 3 investigational sites. Of the 57 implanted subjects, 52 are past the 10 month follow up.

For a summary of key points of comparison between the G000321 study and the G070162 study, please refer to Table I below.

PMA P090018: FDA Summary of Safety and Effectiveness Data

page 14

an an ann an Anna an A Iomraidh an Anna	G070162	G000321
Principle of Operation	No change	-
Device Design	<ul> <li>Minor refinements of G000321 device, for example:</li> <li>Single and dual channel frequency bands</li> <li>Max gain 55 dB</li> <li>Longevity 6 yrs nominal</li> <li>Noise floor 23-28 dB SPL</li> <li>Smaller personal programmer</li> </ul>	<ul> <li>Single channel frequency band</li> <li>Max gain 40 dB</li> <li>Longevity 3.7 yrs nominal</li> <li>Noise floor 30-35 dB SPL</li> </ul>
Surgical Technique	<ul><li>Enhanced intraoperative techniques</li><li>2 step cementing</li><li>Improved ISA testing</li></ul>	<ul><li>Single step cementing</li><li>Original ISA procedure</li></ul>
<ul> <li>Inclusion Criterion</li> <li>Range of air conduction (AC) pure tone thresholds in the implanted ear</li> <li>Speech discrimination test score</li> </ul>	<ul> <li>Relatively wider (with respect to G000321)</li> <li>&gt; 40%</li> </ul>	<ul> <li>Relatively more narrow (with respect to G070162)</li> <li>&gt; 60%</li> </ul>
Implanted Subjects	57	72
1 <sup>st</sup> Analysis of Endpoints	4 month post-activation	2 month post-activation
Primary Effectiveness Endpoints	SRT and WRS are the co-primary effectiveness endpoints.	SRT is the only primary effectiveness endpoint.
SRT Comparison (4 month post-activation)	Avg. 10.6 dB improvement (non-adjusted)	Avg. 3 dB improvement
<ul><li>Primary Safety Endpoints</li><li>Failures</li><li>Bone Conduction Analysis</li></ul>	<ul> <li>3 failures in 3 unique subjects</li> <li>Forehead placement</li> </ul>	<ul> <li>25 failures in 20 unique subject.</li> <li>Mastoid placement</li> </ul>
	L	t

The applicant sought approval for this PMA based on the clinical data obtained under the G070162 study. As discussed above, differences in the surgical procedures precluded pooling of safety and effectiveness data from the two studies.

ŀ

#### A. <u>Study Design</u>

( ...

Ċ

Patient treatments were begun on January 22, 2008 and the patients continue to be followed. The database for this PMA reflected data collected through July 31, 2009 and included 60 patients. There were three investigational sites.

The study was a prospective, multi-center, one-arm, non-randomized, nonblinded study. The outcomes were compared to each subject's baseline pre-implanted hearing aided condition.

## 1. <u>Clinical Inclusion and Exclusion Criteria</u>

Enrollment in the G070162 study was limited to patients who met the following inclusion criteria:

a) Subject is  $\geq 18$  years old.

b) Subject understands the nature of the procedure and has signed the Subject Informed Consent Form prior to the procedure.

c) Subject is willing and able to comply with specified follow-up evaluations and understands the audiological test procedures and use of the *Esteem*® *System*.

d) Subject has mild to severe sensorineural hearing loss between 500 and 4000 Hz in the ear to be implanted with pure tone air conduction threshold levels within the limits of a Hearing Aid (HA) as follows:

Freq (Hz)	500	1000	2000	3000	4000
LL* (dB HL)	30	35	35	35	35
UL* (dB HL)	100	100	100	100	100

\*LL = Lower Level; UL = Upper Level

e) Subject's air-bone gap is no greater than 10 dB at 4 of the 5 following frequencies: 500, 1000, 2000, 3000 and 4000 Hz.

f) Subject has an unaided maximum word recognition score of greater than or equal to 40% with recorded delivery using a phonetically balanced word list at SRT + 40 dB or at maximum tolerable presentation level.

g) Subject is a current user of a properly functioning and appropriately fit hearing aid. This is defined as the subject has used this aid for at least four (4) hours (average) per day (in the ear to be implanted) for at least three (3) months for a new aid or one (1) month for an adjusted aid.

h) Subject's hearing aid, in the ear to be implanted, shall appropriately fit optimally.

page 16

i) Subject has normally functioning Eustachian tube.

j) Subject has normal tympanic membrane.

k) Subject has a normal middle ear anatomy.

1) Subject has adequate space for *Esteem*® *System* implant determined via fine cut temporal bone CT scan.

m) Subject is a native speaker of the English language.

n) Subject is a hearing aid user in the ear to be implanted.

Patients were not permitted to enroll in the G070162 study if they met any of the following exclusion criteria:

a. Subject has a history of post-adolescent chronic middle ear infections, inner ear disorders or recurring vertigo requiring treatment, disorders such as mastoiditis, Hydrops or Meniere's syndrome or disease.

b. Subject has a history of otitis externa or eczema for the outer ear canal and the investigator believes this will affect the *Esteem® System* implantation.

c. Subject has cholesteatoma or destructive middle ear disease.

d. Subject has life expectancy of < two (2) years due to other medical conditions.

e. Subject has retrocochlear or central auditory disorders.

f. Subject is known to be suffering from any psychological, developmental, physical, or emotional disorder that the investigator feels would interfere with the surgery or follow-up testing.

g. Subject has a known history of fluctuating air conduction and/or bone conduction hearing loss over a one-year period of 15 dB in either direction at 2 or more frequencies (from 500 – 4000 Hz).

h. Subject has sudden hearing loss due to unknown cause.

i. Subject has a history of disabling tinnitus, defined as tinnitus which required treatment.

j. Subject is unable to adequately perform audiological testing.

k. Subject has a medical condition or is undergoing a treatment that may affect healing and the investigator does not believe the subject is a good candidate for the trial.

1. Subject has diabetes that is not well controlled with medication or diet and the investigator does not believe in his best medical judgment that the subject would be a good candidate for the trial.

m. Subject is pregnant at the time of device implant.

n. Subject has a history of keloid formation.

o. Subject has known hypersensitivity to silicone.

2. Follow-up Schedule

{

All patients were scheduled to return for follow-up examinations at 4 and 10 months postoperatively.

Preoperative evaluations are listed in Table II. In this table, "Scr/BL" refers to the initial screening evaluation and baseline measurements.

"Proc/Disc" refers to the surgical procedure. "On" and "Act" refer to turning on the device and activating (programming) the device, respectively. "I" refers to the implant side, whereas "N" refers to the non-implant side.

The objective parameters measured postoperatively during the study are included in Table II. Clinical assessment occurred at 2 months, 4 months and 10 months post-operatively. In addition, clinical assessment occurred yearly. Adverse events and complications were recorded at all visits.

		L Proc/4 Disci		Act:	2Mo	4Mo Endpt	<u>10 М</u> бі	Yoarly F
Informed Consent	X				ANTI TRACING OF			
Medical History	X							
Audiological and Hearing Aid History	<u>x</u>							
Current Medications	x	x	X	X	х	X	х	X
Adverse Events	_	x	x	x	x	X	х	x
Device Settings			x	×	X	x	х	x

### Table II. Screening and Follow-Up Requirements.

page 18

Jesting Requirements	nervenser.	i novigen py						The second
Otogram Pre-screen Audiogical Test	X							The second s
APHAB Questionnaire	X				x	X	X	 X
Esteem Questionnaire					х	x	x	<u>``</u>
Otoscope Exam (perform prior to testing)	I		l	1	1	1	1	<u></u>
Tympanogram			I	1	l			
Air Conduction Thresholds	IN		i	1	1	<b>I</b> /N	1/N	
Air Conduction – Aided (Implant) Ear Warble Tone	1							<u> </u>
Bone Conduction Thresholds	IN		J		(1997) - 1993 - 1994 - 1994 - 1994 - 1994 - 1994 - 1994 - 1994 - 1994 - 1994 - 1994 - 1994 - 1994 - 1994 - 1994 	<i>Ι</i> /Ν	1/N	
Most Comfortable Listening Level (MCL)	UN	·		l		1		 I
Uncomfortable Listening Level (UCL)	HN.			1	1			i
Speech Reception Threshold (SRT)- unalded	IIN						- <b>1</b> 4,	·
Speech Reception Threshold (SRT)-aided	I:N			t	1	i	1	1

	Scr7 s BL	Proci Disc	On	Act	2 <b>Mo</b>	4Mo Endpt	10 Mo	Yearly
Word Recognition - unaided	I/N				[			
Word Recognition - aided	ŴN				1	1		I
Quick SIN – Alded	I/N			1	ł	1		1
Quick SIN – Unaided	1/N		·					
Envoygram IT			X	х	X	Х	X	X
CT Scan	x							
X-ray of implanted device		х			1		·	
I=Implanted Ear N=Non-Implant Ear								

## 3. Clinical Endpoints

ţ

## **Co-Primary Safety Objective – Serious Adverse Device Effects**

To determine the incidence of Serious Adverse Device Effects (SADE) and the incidence rate of device failures and replacements.

*Endpoints:* The analysis of the incidence of SADEs and device failures and replacements through the 4-month and 10-month post-activation follow-up.

*Hypotheses:* This objective was to provide an accurate estimate of the SADE rate and device failure and replacement rate associated with the Esteem® System. Therefore, no formal hypothesis tests were conducted.

PMA P090018: FDA Summary of Safety and Effectiveness Data

page 19

## Adjudication of Adverse Events, SADEs, and Device Failures:

Adverse Events were collected throughout the Pivotal Trial. Envoy Medical established a Clinical Events Committee (CEC) that adjudicated clinical adverse events for the Esteem clinical trial.

The CEC was responsible for establishing and approving decision rules and definitions for the determination of clinical adverse events using data collected on Case Report Forms (CRF's) in the trial. The CEC reviewed all AEs and classified each event as serious or not serious and as device related, procedure related, pre-existing, or not related.

The members of the CEC are physicians/PhDs drawn from the Ear, Nose & Throat (ENT) medical community. The CEC is made up of three voting members. At the time of review, there were two otolaryngology surgeons and one audiologist on the CEC. A representative from Envoy Medical chaired the committee meetings, but Envoy Medical states that the CEC chair did not vote during adjudication of AEs.

#### Definitions

The protocol used the following definitions of various categories of Adverse Events.

#### Adverse Event (AE)

An Adverse Event is any undesirable clinical event occurring to a subject, during a clinical trial, whether or not it is considered related to the investigational product. This includes a change in a subject's condition or laboratory results, which has or could have a deleterious effect on the subject's health or well being.

#### Adverse Device Effect (ADE):

An Adverse Device Effect is an Adverse Event related to the investigational device.

#### Unanticipated Adverse Device Effects (UADE)

An Unanticipated Adverse Device Effect is any serious adverse effect on health or safety or any life threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.

Serious Adverse Event (SAE) or Severe Adverse Device Effect (SADE) A Serious Adverse Event (SAE) or Serious Adverse Device Effect (SADE), are events which:

- Result in death
- Is life threatening
- Requires inpatient hospitalization
- Results in persistent or significant disability/incapacity
- Is a congenital anomaly/birth defect
- Requires intervention to prevent permanent impairment/damage

## **Co-Primary Safety Objective – Cochlear Stability**

To demonstrate that the subjects' cochlear function remains unchanged with the Esteem® System as shown by comparison of the subjects' pre-implant baseline bone conduction threshold (BCT) versus the subjects' 4-month and 10-month post-activation BCT.

Endpoint Analysis: Average and individual changes were evaluated per the protocol. Bone conduction was measured with forehead probe placement. Stability was defined as bone conduction threshold change to be within  $\pm 10$  dB.

*Note:* A Safety Algorithm was adopted to measure cochlear stability for any bone conduction results outside the stability range. This Safety Algorithm can be located in Appendix 1 (Section X) below.

**Co-Primary Primary Effectiveness Objective – Speech Reception Threshold** To demonstrate that the Esteem® System improves the speech reception threshold of sensitivity for hearing and identifying speech signals as well as or better than the pre-implant hearing aid (aided condition).

*Endpoint:* Comparison of the speech reception threshold (SRT) using the Esteem® System (4 months post activation) as compared to the pre-implant aided condition.

*Hypothesis:* The 95% Lower Confidence Bound (LBC) for the mean of difference between the SRT at baseline versus four months is greater than or equal to -5 dB.

95% LCB for Mean(Pre-implant aided  $-\mu 4 \text{ month}) \ge -5$ 

#### **Co-Primary Effectiveness Objective – Word Recognition Scores**

To demonstrate that the Esteem® System at the 4 months postactivation visit is as effective as or better than the hearing aid for improving speech discrimination (intelligibility) as shown by the word recognition score at 50 dB HL.

page 21

Lo

*Endpoint:* Comparison of the word recognition score (WRS) using the Esteem® System at 4 months post-activation compared to the pre-implant aided condition.

*Hypothesis:* This objective was to provide a comparison of the WRS at 50 dB HL associated with the Esteem® System versus the baseline aided condition. There is no formal hypothesis and descriptive statistics are to be presented.

Statistical Analysis: The Word Recognition Scores will be compared using the Thornton and Raffin (1978) published upper and lower limits for various word lists based upon percentage scores. An analysis showing the "% better than", "% equal to", and "% below" the aided condition (HA) will be presented.

*Reference:* Thornton AR, Raffin MJ. Speech discrimination scores modeled as a binomial variable. J Speech Hear Res 1978; 21:507-18.

#### Secondary Effectiveness Objectives

No hypothesis testing was pre-specified for any of the secondary endpoints in the protocol.

#### **Pure Tone Average (PTA)**

To demonstrate that the Esteem® System at the 4 month post activation visit improves the 3-frequency (500, 1000, and 2000 Hz) pure tone average (PTA) when compared to the baseline unaided condition.

#### QuickSIN

( :

To demonstrate that the Esteem® System at the 4 month postactivation visit is as effective as or better than the hearing aid for improving speech discrimination (intelligibility) as shown by the QuickSIN (speech in noise) test results.

#### **APHAB Quality of Life (QOL)**

To show that the Esteem® System improves Quality-of-Life when compared to the baseline aided condition as shown by APHAB scores.

#### Esteem Questionnaire Quality of Life (QOL)

To gather subject feedback and comments on the use of the Esteem® System relative to the pre-implant hearing aid (aided condition) as shown by the Esteem® Questionnaire.

## B. Accountability of PMA Cohort

For the pivotal study (G070162), 57 of 60 enrolled subjects were successfully implanted with the study device at three study sites: 22 subjects at Southeastern ENT & Sinus Center in Greensboro, NC; 18 subjects at Shohet Ear Associates Medical Group in Newport Beach, CA; and 17 subjects at Lahey Clinic in Burlington, MA (Table III). Among the 57 implanted subjects, 54 subjects completed the 4-month follow-up (3 subjects had revision surgery due to limited benefit and were excluded from the analysis of the primary and secondary effectiveness outcomes) and 52 subjects completed the 10-month follow-up.

Of the 60 enrolled subjects, three were not implanted. Two patients were enrolled, underwent surgery, but did not receive the implant because the middle ear space was inadequate. A third subject decided to withdraw from the study after signing the consent form.

Of the 57 implanted subjects, three did not make the 4-month follow-up because of revision surgery.

Of the 54 subjects who reached the 4-month follow-up, two subjects did not reach the 10-month follow-up. The first of these subjects was explanted due to an incision breakdown that would not heal (possibly related to a smoking habit). A second subject had not been scheduled for the 10-month follow-up at the time the data base was finalized.

		Total Implanted	4-month Follow-Up N (%)	10-month Follow-Up N (%)
All		57	54 (94.7)	52 (91.2)
Southeastern ENT & Sinus Center		22 •	21 (95.5)	21 (95.5)
Shohet Ear Associat	es Medical Group	18	18 (100.0)	16 (88.9)
Lahey Clinic	-	17	15 (88.2)	15 (88.2)

#### Table III. Patient Accountability by Site and Follow-Up Visit.

(

#### C. Study Population Demographics and Baseline Parameters

The subject demographic data is summarized in Table IV. The subjects' average age was 52.9 years, ranging from 18 to 77 years; 67% (38) were male and 33% (19) were female. Fifty six (56) of the 57 implanted subjects with available baseline data were Caucasian (98%), and one subject was Asian. At the time of study enrollment 25% (14) were retired, 9% (5) worked part time, and 51% (29) worked full time. Fifty four

PMA P090018: FDA Summary of Safety and Effectiveness Data

page 23

(54) of the 57 subjects (95%) suffered a gradual hearing loss that was diagnosed at an average age of 32.5 years, ranging from 1 to 66 years.

The degree of hearing loss, based on pure tone average (PTA), was mild in 3 subjects, moderate in 44 subjects and severe in 10 subjects (Table IV). All 57 (100%) subjects were current users of a hearing aid with average usage time of 13.7 years, ranging from 0.4 to 37.8 years. Of the subjects implanted, 49 (86%) subjects used hearing aids in both ears.

Demographics	Mean ± SD <sup>*</sup> n (min, max)	Degree of Hearing Loss (implanted ear)	N/Total (%)
Age (years)	52.9 ± 15.8	Mild (PTA $\leq$ 40 dB)	3/57 (5.3%)
	57 (18.0, 77.2)	Moderate (41 dB $\leq$ PTA $\leq$ 55 dB)	25/57
			(43.8%)
	N/Total (%)	Moderate Severe (56 dB $\leq$ PTA $\leq$ 70 dB)	15/57
			(26.3%)
Gender		Severe (PTA $>$ 71 dB)	10/57
Male	38/57 (66.7%)		(17.6%)
Female	19/57 (33.3%)		
Race/Ethnicity			
White/Caucasian	56/57 (98.2%)	• *	
Black/Non-Hispanic	0/57 (0%)		
Hispanic	0/57 (0%)		
Asian	1/57 (1.8%)		
Work Status			
Full Time Employee	29/57 (50.9%)		
Part Time Employee	5/57 (8.8%)		
Retired	14/57 (24.6%)		
Unemployed	4/57 (7.0%)		`  .
Other	5/57 (8.8%)	· · · · · · · · · · · · · · · · · · ·	

#### Table IV. Subject Demographics and Degree of Hearing Loss.

#### **D.** Safety and Effectiveness Results

1. Safety Results

The analysis of safety was based on the cohort of 60 subjects. The key safety outcomes for this study are presented below in Tables V to XIV and Figure 2. Adverse effects are reported in Tables V, VI, IX, XI-XIII, and Figure 2.

## Adverse effects that occurred in the PMA clinical study:

## Severe Adverse Device Effect (SADE)

6

The CEC determined that there were 6 SADEs reported in 6 subjects, for an incidence of 10.5% (6/57), as shown in Table V. Among the SADEs, three were due to limited benefit which resulted in revision procedures. One subject had incision site infection. One other subject had incision breakdown. The sixth subject experienced severe pain and facial weakness which resolved with medication.

Subject #	Event	Total Number	Intervention	Status
103-24 MIEKU	Severe pain and Facial Weakness	1	Medication	Resolved
109-34 CHWYA	Incision Site Infection	1	Medication	Resolved
103-22 JELGR 102-22 DAAKU 109-24 CRBAR	Limited Benefit	3	Revision Procedures with replacement of parts of the Device	1 Subject has reached 4 month Endpoint, Remaining 2 Subjects have reached 2 month post-operative period, but not the 4 month Endpoint at the time of this report
105- 37 LADGO	Incision Breakdown	1	Required Explantation	Reconstructed with Incudoplasty
Total SADE Events		6	<u> </u>	

Table V. Sev	ere Adverse Devi	ice Effects (SADI	Es). Co-Primar	y Safety	Endpoint.

For more detail concerning the 3 patients with Limited Benefit and 1 patient who required explanation, refer to Table VI.

ZD

Table VI. Device	Failure/Revisions/Explants and Reconstruction,

. (

í

(

Subject #	Event	Implant	Elapsed	Revision/	Findings at Surgery	Reimplant
		Date	time to	Explant	i mangs at surgery	/Reconstruction
<u> </u>	· ·		resolution	Date	·	Method
103-22	Limited Benefit	1/30/08	8.5 months	10/16/08	Fibrous Adhesions	Replaced
JELGR	shortly after				fixing sensor to	Sound
	Activation				incus and Driver	Processor and
					Additional	Sensor
					observation:	
					MedCem butted	
	-		1		against the short	•
	-			}	process of incus	
					causing lower than	
					expected Sensor	
					and ISA test	
				ļ	performance at	
100.00	T I D	<u> </u>			implant.	
109-22	Limited Benefit	5/16/08	12.5	5/29/09	Extensive Fibrous	Replaced
DAAKU	at Activation		months		adhesions in the	Sound
-					facial recess	Processor and
					surrounding the	Driver
					Driver and stapes.	
			-		Additional observation: An	
				]	unusually small	
					amount of	
					EnvoyCem was	
				Ì	present to form the	
					Driver to Stapes	
					connection.	
109-24	Limited Benefit.	5/30/08	11 months	5/01/09	Extensive Fibrous	Replaced
CRBAR					adhesions noted in	Sound
	· · ·				the facial recess	processor and
					surrounding the	Driver
			-		Driver and stapes.	
1					Additional	
					findings: Driver tip	
					pulled away from	
					stapes & unusually	
					small amount	
			)		EnvoyCem	
105-37	Repeated	6/27/08	8months	2/27/09	Incision had a large	Reconstructed
LAGDO	Incision				opening under the	with
			1			******

#### Device Failure Summary

ł

(

A failure summary was presented by the applicant for 3 subjects that received Limited Benefit from the device as follows:

Subject 103-22 JELGR reported a decrease in benefit shortly after Activation, continuing through the 2-month follow-up visit. Diagnostic testing indicated that the Sensor output was lower than normal. The revision procedure found extensive dense fibrous adhesions filling the facial recess. The fibrous adhesions had fixed the Sensor to the incus and the Driver to the malleus. In order to remove the fibrous adhesions, the surgeon had to remove the Sensor and Driver and replace them with new components. During this process, surgeon noticed some MedCem butted against the short process of the incus, restricting its movement. He removed this obstruction in order to restore mobility of the incus. The new Sensor, Driver and System tests were conducted with acceptable results. The surgeon's conclusion was that the dense fibrous adhesions that formed after implant prevented the Sensor and incus from moving properly causing the poor performance. The MedCem attached to the incus likely was the cause of lower than expected Sensor and System ISA test performance at implant but as indicated by the data the fibrous adhesions that developed after Activation were the cause of the decrease in benefit.

Subject 109-24 CRBAR reported limited benefit at Activation that progressively worsened through the 2-month follow-up. Diagnostic testing indicated that the Driver output was lower than normal. The revision procedure showed extensive fibrous adhesions in the facial recess surrounding the Driver and stapes. The Sensor was functioning properly and not affected by the adhesions. During removal of the fibrotic tissue, The surgeon found that the Driver tip had been laterally pulled away from the stapes EnvoyCem connection and that an unusually small amount of EnvoyCem was present to form the Driver-stapes connection. This subject had a small facial recess opening that could have affected visibility and the original application of EnvoyCem. The surgeon implanted a new Driver and used EnvoyCem to complete the connection to the stapes. The new Driver, Sensor and System tests were conducted with acceptable results. The conclusion was that the fibrous adhesions that formed after implant likely prevented the Driver and stapes from functioning properly causing the limited benefit.

Subject 109-22 DAKKU reported limited benefit at Activation that progressively worsened through the 2-month follow-up. Diagnostic testing indicated that the Driver output was lower than normal. The revision procedure showed extensive fibrous adhesions in the facial recess surrounding the Driver and stapes. The Sensor was functioning properly and not affected by the adhesions. During removal of the fibrotic tissue, the surgeon found that an unusually small amount of EnvoyCem was present to form the Driver-stapes connection. This subject had a small facial recess opening that could have affected visibility and the original application of EnvoyCem. The surgeon implanted a new Driver and used EnvoyCem to complete the connection to the stapes. The new Driver, Sensor and System tests were conducted with acceptable results. The conclusion was that the fibrous adhesions that formed after implant likely prevented the Driver and stapes from functioning properly causing the limited benefit.

#### **Bone Conduction Threshold - Cochlear Stability**

The objective was to demonstrate that the subject's cochlear function remains unchanged with the Esteem® System as shown by comparison of the subject's pre-implant baseline Bone Conduction Threshold (BCT) vs. the subject's 4-month and 10-month post-activation BCT. Average and individual changes were evaluated per the protocol. Bone conduction was measured with forehead probe placement. Stable results should be within  $\pm$  10 dB. A Safety Algorithm (Appendix 2) was adopted to measure cochlear stability for any bone conduction results outside the stability range.

At the group level, changes in bone conduction threshold were used to determine whether the Esteem® System caused damage to residual cochlear function. The average 3-frequency (500, 1000, 2000 Hz) bone conduction change from baseline for all subjects was  $0.1 \pm 0.9$  dB (mean  $\pm$  standard error) at 4 months and  $-0.8 \pm$ 1.1 dB (mean  $\pm$  standard error) at 10 months (Table VII). This small change is indicative of no systemic cochlear damage being caused by either the implant or the therapy.

PMA P090018: FDA Summary of Safety and Effectiveness Data

(

page 28

X	The second s	10 M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	The second as second the second		
	500 Hz	1000 Hz	2000 HZ	'4000 Hz	PTA -
	mean <u>+</u> se 👘	mean 🕂 se 📑	mean <u>+</u> se	mean + se	mean + se -
	(CI range)	r(CI frange)	(CI,range)	(CI inige)	(CI range)
Pre-	45.0±1.9	57.5±1.7	66.6±1.4	65.0±1.7	56.3±1.3
Implant	(41.3, 48.7)	(54.1, 60.8)	(63.7, 69.4)	(61.5, 68.5)	(53.7, 58.9)
4-Month	45.4±1.9	57.9±1.6	67.4±1.3	65.6±1.5	56.4±1.3
	(41.7, 49.1)	(54.6, 61.1)	(64.8, 70.0)	(62.6, 68.6)	(53.7, 59.0)
Mean	$0.0 \pm 0.9$	$0.0 \pm 1.0$	$2.2 \pm 1.3$	$1.2 \pm 1.2$	0.1 ± 0.9
Difference	(-1.8, 1.8)	(-2.0, 2.0)	(-0.4, 4.8)	(-1.3, 3.7)	- (-1.7, 2.0)
		が、「			
10-Month	42.6±2.0	56.9±1.6	68.0±1.4	66.3±1.5	55.3±1.5
	(38.7, 46.5)	(53.8, 60.1)	(65.2, 70.7)	(63.4, 69.3)	(52.3, 58.3)
Mean	-2.3±1.0	-0.3±1.2	1.3±1.4	2.2±1.3	-0.8±1.1
Difference	(-4.4, -0.3)	(-2.7, 2.0)	(-1.5, 4.1)	(-0.5, 4.8)	(-3.1, 1.5)

Table VII. Average Bone Conduction Threshold Results (reported as mean +/- standard error).

There was no mean change in bone conduction threshold at 4-months relative to the baseline for frequencies 500 and 1000 Hz ( $0.0 \pm 6.4 \text{ dB}$ ,  $0.0 \pm 7.0 \text{ dB}$ , respectively; mean  $\pm$  standard deviation). There were slight increases in the bone conduction threshold for frequencies 2000 and 4000 Hz ( $2.2 \pm 7.8 \text{ dB}$ , and  $1.2 \pm 7.6 \text{ dB}$ , respectively; mean  $\pm$  standard deviation).

At the individual level, all subjects with 4-month and 10-month data in the database as of July 27, 2009, were analyzed according to the change criteria adopted in bone conduction (BC) and safety algorithm (SA) in accordance with the clinical protocol (i.e., 2 out of 4 frequencies change greater than 10 dB or 1 frequency greater than 20 dB; for details, see Appendix 2). Out of 54 subjects who had 4-month follow-up, the BC/SA threshold could not be determined in two subjects (0204-103-34-CYJTA and 0204-109-27-BRTGR) at one or more frequencies due to equipment limits. For the remaining 52 subjects, no subjects had a BC/SA threshold shift at the 4-month endpoint greater than the protocol criteria. At 10 months, the applicant reported that 52 subjects had the BC/SA data. The BC/SA threshold could not be determined at one or more frequencies in one subject (0204-109-27-BRTGR) due to equipment limits. Of the 51 subjects, one subject (0204-103-28-TOSTR) had a BC/SA threshold shift of greater than 20 dB at 4000 Hz.

The more consistent and stable bone conduction measurements in G070162 compared to G000321 may be due to the forehead probe placement versus the mastoid probe placement. Bone conduction was shown to be stable through the 4-and 10-month intervals.

PMA P090018: FDA Summary of Safety and Effectiveness Data

(;

In a worst-case scenario under the intent to treat population, 13% (8 out of 60) and 15% (9 out of 60) of the study cohort does not meet this safety objective at 4and 10-month follow-up, respectively. At the 10-month follow-up, one subject (103-28) had a BC/SA threshold shift greater than the protocol criteria at the 4000 Hz.

A summary of clinical safety outcomes is provided in Table VIII.

Clinical Protocol Objectives	4 Month Results	10 Month Results
<ul> <li>Primary Safety Objective:</li> <li>Serious Adverse Device Effects (SADE)</li> <li>Incidence of Device Failures and Replacements</li> </ul>	<ul> <li>SADE</li> <li>Three (3) subjects for facial weakness / incision issues</li> <li>Three (3) subjects for revision procedures to date</li> <li>SADE rate: 10.5% (6 of 57)</li> <li>Failures</li> <li>Three (3) failures resulting in approved revisions were reported in three unique subjects prior to the 4-month follow-up</li> <li>Failure rate: 5.3% (3 of 57)</li> </ul>	<ul> <li>SADE</li> <li>No additional SADE were reported between the 4- month and 10-month follow- up visits</li> <li>Failures</li> <li>No additional failures were reported between the 4- month and 10-month follow- up visits</li> </ul>
<ul> <li>Primary Safety Objective:</li> <li>Bone conduction (BC) threshold at 4 months post- activation vs. pre-implant</li> <li>Safety Algorithm (SA) for those that fail BC</li> </ul>	<ul> <li>Bone Conduction</li> <li>Average 3 frequency (500, 1K, 2K) bone conduction change of 0.1 dB at 4 months vs. pre-implant.</li> <li>Individually, no subjects (0) at 4 months had BC/SA change per the protocol criteria from pre-implant.</li> </ul>	<ul> <li>Bone Conduction</li> <li>Average 3 frequency (500, 1K, 2K) bone conduction change of -0.8 dB at 10 months vs. pre-implant.</li> <li>Individually, one subject (1) at 10 months had BC/SA change per the protocol criteria from pre-implant at 4 kHz.</li> </ul>

#### Table VIII. Summary of Clinical Safety Data.

ί.

į.

#### Adverse Event Results

The list of reported adverse events related to the device as determined by the CEC are shown in Table IX (as provided by the applicant in the PMA):

- 96 ADEs were reported in Table IX if they were found during CEC adjudication to be not serious and were found to be caused by the mastoidectomy w/facial recess, device, peri-operative surgery related, or device implant procedure related.
- The majority of these Adverse Effects were classified as mild or moderate.
- 70% of the ADEs have resolved.
- The remaining 30% of the ADEs are ongoing for over a year at the time of this report. Ongoing ADEs include conditions like taste disturbance, facial weakness/paralysis, tinnitus, dizziness, middle ear effusion, and ear pain.

PMA P090018: FDA Summary of Safety and Effectiveness Data

page 30

3Ś

The list of reported adverse events that are not device related as determined by the CEC are shown in Table X:

- Events were classified as AE's if they were found during CEC adjudication to ٠ be caused by underlying or concomitant illness, concomitant medications, or other causes.
- Seventeen events were classified as mild, 4 as moderate, and 1 as severe. ٠
- Of the 29 AEs reported, 21 (72%) have resolved. .
- 8/29 AEs (28%) were still ongoing at the time of this report. •

Event Transform	Mild 🖓	🐘 Moderate 👔	Rate Severe 7	💒 Total
Aural Fuliness	2	0	0	2
Blistering TM	1	0	0	1
Chest Pain	1	0	0	1
Discomfort above Incision	1	1	0	2
Dizziness	1	0	0	1
Dry Eye	1	0	0	1
Disequilibrium	3	0	0	3
Ear Cracking	2	0	0	2
Ear Pain	4	0	0	4
Ear Roaring	1	0	0	1
Eye Irritation	1	0	0	1
Eye Squint	1	0	0	1
Facial Weakness/Paralysis	2	1	0	3
Feedback	1	0	0	1
Fluid	3	6	0	9
Headache	1	1	0	2
Imbalance	1	0	0	1
Incision Discomfort	3	0	0	3
Incision Drainage	1	0	0	1
Limited Benefit	1	0	0	1 1
Metallic Taste	1,	0	0	1
Middle Ear Effusion	- 8	0	0	8
Moist Debris	1	0	0	1
Nasal Drainage	1	0	0	1
Noise	1	0	0	1
Numbness	1	0	0	1
Otitis Externa	2	0	0	2
Otalgia	2	0	0	2
Pain	2	0	0	2
Taste Disturbance	23	1	0	24
Tinnitus	8	0	0	8
TM Perforation	1	0	0	1
Tongue Numbness	1	0	0	1
Unsteadiness	1	0	0	1
Vertigo	0	1	0	1
TOTAL	2 Jac 85 1 8 %	₩. ≈ \$ <b>11</b> *	704. J. 108-542	96

Table IX. CEC-ad	judicated Adverse I	Device Effects (9)	6 Events in 43 Subjects).

(

(

36

Event Event	Mild	Moderate	Severe Severe	Total
Apnea	1	0	0	1
Dizziness	1	0 .	0	1
Ear Canal Wound	0	0	1	1
(non-implant ear)				
Eustachian Tube	1	0 \	0	1
Dysfunction				
Headache	1	0	0	1
Imbalance	1	0	0	1
Knee Pain	1	0	0	1
Light Headedness	1	0	0	1
ME Effusion	1	0	0	1
ME Fluid	1	0	0	1
Motor Vehicle Accident	1	0	0	1
Mucosal Inflammation	0	1	0	1
Nose bleed	2	0	0	2
Pain	0	. 1	0	1
Post Nasal Dramage	1	0	0	1
Rapid Heart Rate	1	0	0	1
Rash Abdominal	1	0	. 0	1
Root Canal	1	0	0	1
Sinus Infection	2	0	0	2
Sprained Ankle	0	1	0	1
Touch Sensation	1	0	0	1
Tinnitus	0	1	. 0	1
URI	2	0	0	2
Vertigo	2	0	0	2
Yeast infection	1	. 0	0	1
TOTAL	24 24	编刊、编辑和学生主义	日天之经生19月2日日,19月	5位:11-370 4 1-1

Table X. CEC-Adjudicated Adverse Events (29 Events in 25 subjects).

Table XI, Table XII, Table XIII, and Figure 2 have been compiled by FDA from a spreadsheet provided by the applicant which includes all adverse events. All events have been grouped into 9 broad categories of Taste, Middle Ear Effusion, Pain, Tinnitus, Imbalance/Dizziness, Facial Paresis, Limited Benefit, Headache, and Miscellaneous. Table XII summarizes all 133 adverse events observed during this study and subject status at the time of this PMA submission. Table XII presents a detailed description of the adverse events in each of the 9 categories. The following observations can be made from these two tables:

• Of the 133 adverse events, 78% have resolved, 21% remain unresolved, and the status of 1 event is unknown.

• The most frequent adverse event was taste disturbance (24 of 57 subjects, 42%). This adverse event has not resolved for 8 subjects (14%).

• Facial paresis/paralysis was reported in 7% of subjects with 1% still reported to be ongoing after one year.

PMA P090018: FDA Summary of Safety and Effectiveness Data

page 32

- 52 (91%) of 57 subjects experienced AEs; 36 of 52 Subjects experienced
- multiple (2-8) AEs, not all events are resolved; 26 Subjects have ongoing AEs.

Adverse Number Number of Number Number of Number Number of Number of Number of Event (AE) of AEs Subjects of Subjects with of AEs Subjects AEs with Subjects Categories (% of with AEs Resolved **Resolved AEs** Ongoing with Resolution with total (% of 57 AEs (% of 57 (% of Ongoing Status Resolution AEs) implanted (% of implanted category) AEs Unknown Status subjects) category) subjects) (% of 57 (% of Unknown implanted category) (% of 57  $\sim 1$ subjects) implanted subjects) Taste 25 (19%) 24 (42)% 16 (64%) 15 (26%) 8 (32%) 8 (14%) 1(4%)1 (2%) Disturbance Middle Ear Effusion 18 (14%) 18 (32%) 18 (100%) 18 (32%) 0 0 0 0 12 (9%) 4 (33%) Pain 12 (21%) 8 (67%) 8 (14%) 4 (7%) 0 0 Imbalance/ Vertigo 11 (8%) 11 (19%) 9 (82%) 9 (16%) 2 (18%) 2 (4%) 0 0 /Dizziness Tinnitus 10 (8%) 10 (18%) 7 (70%) 7 (12%) 3 (30%) 3 (5%) 0 0 Facial Paresis/ 4 (3%) 4 (7%) 2 (50%) 2(4%)2 (50%) 2 (4%) 0 0 Paralysis 4 (3%) 4 (7%) 4 (100%)\* inited 4 (7%) 0 0 0 0 Jnefit 3 (2%) Headaches 3 (5%) 3 (100%) 3 (5%) 0 0 0 0 Miscella-46 (34%) 30 (52%) 37 (80%) \*\* 9 (20%) \*\* 0 0 neous \*\*\* \*\*\* 133 Total 52 (91)% 104(78%) 28 (21%) 1(.008%)1 (2%) (100%)

Table XI. Categories of Adverse Events and Status.

Ĺ

\*1 Subject resolved without intervention, 1 Subject has reached the 4 month Endpoint; 2 Subjects have only reached 2 month post-operative period, but not the 4 month Endpoint at the time of this report. \*\* 12 of 30 Subjects (40%) experienced 2-4 AEs in Miscellaneous category, not all events resolved; 12 Subjects have ongoing AEs

\*\*\* 36 of 52 Subjects experienced 2-8 AEs, not all events resolved; 26 Subjects have ongoing AEs

Adverse Event Category	Description of Adverse Event	Number of	
		Events	
Taste Disturbance		25	
	Taste Disturbance	18	
	Metallic Taste	3	
	Altered Taste	1	
	Disturbed Taste	1	
	Taste Disturbance	1	
	Taste Disturbance (Delayed Onset)	1	
Middle Ear Effusion		18	
	Middle Ear Fluid	5	
	Effusion	3	
	Fluid Behind TM	2	
	Crackling Sound	1	
	Crackling Drainage Sound	1	
	Effusion (R)	1	
	Fluid AS	1	
	Middle Ear Effusion	1	
	Middle Ear Fluid	1	
	Middle Ear Effusion , Rt. Ear, Implant Ear	I	
	Residual Effusion L Middle Ear	1	
Pain		12	
	Otalgia	2	
	Discomfort Above Implant	1	
	Discomfort/Pain R Side of Head	1 .	
	Ear Canal Pain	1	
	Ear Pain	1	
	Ear Pain/Pressure	1	
	Intermittent Otalgia	1	
	L Ear Pain	1	
	Pain Around Incision	1	
	Pain in Temporal Region /Cheek	1	
	Pain/Incision discomfort	1	
Vertigo/Dizziness/Imbalance		11	
	Vertigo	3	
	Dysequilibrium	2	
	Imbalance	1	
	Mild Dysequilibrium	1	
	Unsteadiness	1	
	Unsteadiness	1	
	Dizziness	2	
Tinnitus		10	
· · · · · · · · · · · · · · · · · · ·	Tinnitus Left Ear	2	
	Right Ear Roaring	1	
	Slight Increase in Tinnitus	1	
	Tinnitus Left Ear	1	
	Tinnitus	5	
Facial Paresis		4	

Table XII. Description of Adverse Events with Categories.

í

(

(

PMA P090018: FDA Summary of Safety and Effectiveness Data

page 34

	Facial Palsy	1
	L Facial Paresis	1
	Facial Weakness	1
	R Facial Weakness	1
Limited Benefit		4
· · · · · · · · · · · · · · · · · · ·	Limited Benefit *	1
	Limited Benefit **	1
	Limited Benefit **	
	Limited Benefit **	1
Headaches		3
	Headache	1
	Headache	
	Frontal Headache	
Miscellaneous		1
Miscenaneous		46
	Aural Fullness	2
	Nose Bleed	2
	Sinus Infection	2
	Motor Boat Sound/Shorting Out of Sound	2 (1 each)
	URI	2
	Ankle Trouble/Broken leg	2 (1 each)
	Apnea (pre-existing)	1
	Incision Breakdown (1), Infection(2), and	
	Discomfort (1)	4
•	Nasal Drainage/Post Nasal Drip	2 (1 each)
	TM Perforation/TM Blistering	2 (1 each)
	Otitis Externa (1), Debris in Ear Canal (2), and Sore	, ,
	in Ear Canal (1)	4
	Eustachian Tube Dysfunction/Feedback	2 (1 each)
	TIA, Chest Pain, Knee Pain, Pregnancy, MVA	5(1  each)
	Rapid Heart Beat, Rash, Tooth Pain	3 (1 each)
	Yeast Infection, Discomfort, Light Headedness	3 (1 each)
	Hair Follicle Incision and Blood Fluid (L)	2(1  each)
	Dry Eye, Eye Irritation, Eye Squint	3 (leach)
	Numbness, Numbness of left Tongue, Numbness of	
	Tongue	3 (1 each)
	Tongue	5 (Teach)
Grand Total		133

\* One Subject with Limited Benefit improved without intervention

\*\* Three Subjects with Limited Benefit underwent revision surgery

Figure 2 represents the breakdown of adverse events by each of the three sites. Table XIII verifies that Site 109 has very few ongoing Adverse Events as compared to Site 103 and 105. Figure 2 and Table XIII show that there is wide variability of reported Adverse Events across the three sites that participated in this study.

PMA P090018: FDA Summary of Safety and Effectiveness Data

(

Adverse Events	Site 103	Site 105	Site 109	Grand Total
Not Resolved, No Follow Up Necessary		1	·	-
Ongoing at the Time of Report	15	19	3	37
Recovered, No Residual Effects	35	45	14	94
Unknown		1		1
Grand Total	50	66	17	133
Number of Subjects Implanted	N=22	N=18	N=17	N=57

Table XIII. Status of Adverse Events by Clinical Site.

(:




Figure 2. Numbers of adverse events grouped by category and site.

## Unanticipated Adverse Device Effect (UADE)

The Clinical Events Committee (CEC) determined that there were no UADEs reported during this trial.

PMA P090018: FDA Summary of Safety and Effectiveness Data

page 36

#### Severe Adverse Events (SAE)

A total of two events have been reported which were classified as SAEs:

- Broken leg (recovered)
- Transient ischemic attack (recovered)

#### 2. Effectiveness Results

۱.,

í

( ; ·

#### Speech Reception Threshold (SRT)

The criterion used is that the 95% Lower Confidence Bound (LBC) for the mean of difference between the SRT at baseline versus four months is greater than or equal to -5 dB.

The mean SRT decrease at 4 months from baseline (pre-implant, aided) was 10.6 with a 95% confidence interval ranging from 7.1 to 14.2 (Table XIV).

			contino (Onnajastea)
Follow-up Period		s SRT (m dB) mean ± se n (mm max)	
	Pre-Implant Aided	4-Month⇒ sis	10-Month
	41.2 ± 1.5	$30.6 \pm 1.6$	29.4 ± 1.6
	57 (38.3, 44.1)	54 (27.4, 33.7)	52 (26.1, 32.7)
Mean Improvement	NA	10.6 ± 1.8	$11.4 \pm 1.8$
(95% CI)		(7.1, 14.2)	(7.7, 15.2)

Table XIV. Mean Improvement in SRT Scores at 4 and 10 Months (Unadjusted).

However, as shown in Table XV the heterogeneity in the treatment effect among sites is statistically significant (p-value < 0.01). Overall, the mean SRT improvement with the Esteem® compared to the preimplant hearing aid was 10.6 dB with the site-specific mean improvement between 1.3-16.9 dB.

# Table XV. Mean Speech Reception Threshold (SRT) Decrease at 4-Months Relative to the Baseline (Aided Condition) for the Three Investigational Sites.

Analysis	Site 103	Site 105	Site 109	P-value for Site
· · · · · · · · · · · · · · · · · · ·	Mean±SE	Mean±SE	Mean±SE	Differences
Unadjusted	11.9±2.6	16.9±2.8	1.3±3.0	< 0.01

#### Word Recognition Score

The applicant's objective was to demonstrate that the Esteem® at the 4 months post-activation visit is as effective as or better than the hearing aid for improving speech discrimination (intelligibility) as shown by the word recognition score at 50 dB HL.

The endpoint was the comparison of the word recognition score (WRS) using the Esteem® at 4 months post-activation compared to the pre-implant baseline aided condition. The applicant indicated that the objective of WRS was to provide a comparison of the Word Recognition Scores at 50 dB HL associated with the Esteem versus the baseline aided condition. The applicant did not propose any formal hypothesis, and the WRS was analyzed using the method described by Thornton and Raffin (Speech discrimination scores modeled as a binomial variable; J Speech Hear Res 1978; 21:507-18) regarding upper and lower limits for various word lists based upon percentage scores. An analysis showing the "% better than", "% equal to", and "% below" the pre-implant baseline aided condition was presented.

As reported, Table XVI displays the WRS results at the 4- and 10-month intervals. At 4 months, 93% of the subjects' WRS was as good as or better than that in the aided baseline condition (HA), and 7% exhibited below. The percentage of subjects having equivalent or better than HA decreased to 88% at 10 months, and those exhibiting below HA increased to 12%.

	All Subjects					
	4 Month N=54	10 Month N=52				
% Better HA	30/54 (56%)	32/52 (62%)				
% = HA	20/54 (37%)	14/52 (27%)				
% Below HA	4/54 (7%)	6/52 (12%)				

Table XVI. Word Recognition Scores	(WRS) at 50 dB HL.
------------------------------------	--------------------

The mean change in WRS at the 4-month visit was 21.7%, with a 95% confidence interval of 13.3 to 30.1 (Table XVII). However, as also observed in the SRT endpoint data, there is statistically significant heterogeneity in WRS among the sites (Table XVIII, p=0.01). The mean change in WRS at 4-months varied from 3.6 to 37.1 and at 10-months varied from 0 to 32.4, depending on the site.

#### Table XVII. Mean Change in WRS at 4-Month Follow-Up.

	Unadjusted
Follow-up	Mean $\pm$ SE
	(95% CI)
4 Months	$21.7 \pm 4.2$
	(13.3, 30.1)
10 Months	$19.8 \pm 4.3$
	(11.1, 28.4)

PMA P090018: FDA Summary of Safety and Effectiveness Data

page 38

	Site 103 N (%)	Site 105 N (%)	Site 109 N (%)
Better HA	11 (52.4)	15 (83.3)	4 (26.7)
= HA	9 (42.9)	3 (16.7)	8 (53.3)
Below HA	1 (4.8)	0 (0.0)	3 (20.0)

Table XVIII. Word Recognition Score at 4-Months Compared to Baseline.

Overall, 93% of Esteem® recipients scored equal to or better than their preimplant hearing aid. A summary of the WRS data found in Tables XVI and XVIII follows:

- 7% scored less than their pre-implant hearing aid (0%-20% depending upon clinical site),
- 37% scored equal to their pre-implant hearing aid (17%-53% depending upon clinical site), and
- 56% scored better than their pre-implant hearing aid (27%-83% depending upon clinical site).

#### Secondary Effectiveness Endpoint Analysis Pure Tone Average (PTA)

The objective was to demonstrate that the Esteem System at the 4-month postactivation visit improves the 3-frequency (500, 1000, and 2000 Hz) pure tone average (PTA) when compared to the baseline unaided condition. For each subject, the 4-month, as well as the 10-month, air conduction data were compared to the baseline unaided data at various frequencies (Hz).

Table XIX details the mean air conduction change and the number of subjects in each functional "benefit" group at each frequency. The data is also plotted in Figure 10. There were 96% (52/54) of subjects at the 4-month interval and 92% (48/52) at the 10-month interval who had PTA change greater than 10 dB.

Table XIX. Air Conduction Threshold Change at 4 and 10 Months.

	Air Conduction Thresholds 4 Months N≡54 <sup>+</sup>								
	5250% 下学家	\$500 <u>5</u> 8.22	1000	2000.2 3	3000		6000 z	8000 >	PTA 💿 🖘
Mean delta from Baseline ± SE (CI range)	$12 \pm 2$ (16, 8)	19 ± 2 (22, 16)	26 ± 2 (30, 23)	35 ± 2 (39, 32)	23 ± 2 (27, 19)	17 ± 2 (21, 12)	8 ± 2 (12, 4)	0 ± 2 (5, -5)	27 ± 1 (30, 24)
% Greater than +10 dB	25/54 (46%)	38/54 (70%)	49/54 (91%)	51/54 (94%)	44/54 (81%)	35/54 (65%)	23/54 (43%)	8/54 (15%)	52/54 (96%)
% Stable (±10 dB)	28/54 (52%)	16/54 (30%)	5/54 (9%)	3/54 (6%)	8/54 (15%)	16/54 (30%)	20/54 (37%)	23/54 (43%)	2/54 (4%)
% Less than -10 dB	1/54 (2%)	0/54 (0%)	0/54 (0%)	0/54 (0%)	1/54 (2%)	2/54 (4%)	6/54 (11%)	7/54 (13%)	0/54 (0%)
% No Response	0/54 (0%)	0/54 (0%)	0/54 (0%)	0/54 (0%)	1/54 (2%)	1/54 (2%)	5/54 (9%)	16/54 (30%)	0/54 (0%)

			Air	Conduction	n Threshold N=52	ls 10 Month	is za		
	<i>,</i> 250 ;	\$ <b>500</b> 28 - 5	1000_5	2000 *	3000	<u>4000 抗</u>	6000	8000	PTA
Mean delta from Baseline ± SE (CI range)	11 ± 2 (15, 8)	$20 \pm 1$ (23, 17)	27 ± 2 (30, 23)	36 ± 2 (40, 33)	26 ± 2 (30, 22)	18 ± 2 (22, 14)	10 ± 2 (15, 5)	$1 \pm 3$ (6, -5)	27 ± 1 (30, 25)
% Greater than +10 dB	23/52 (44%)	40/52 (77%)	46/52 (88%)	49/52 (94%)	43/52 (83%)	35/52 (67%)	25/52 (48%)	10/52 (19%)	48/52 (92%)
% Stable (±10 dB)	29/52 (56%)	12/52 (23%)	5/52 (10%)	3/52 (6%)	6/52 (12%)	13/52 (25%)	16/52 (31%)	20/52 (38%)	4/52 (8%)
% Less than -10 dB	0/52 (0%)	0/52 (0%)	1/52 (2%)	0/52 (0%)	1/52 (2%)	3/52 (6%)	6/52 (12%)	6/52 (12%)	0/52 (0%)
% No Response	0/52 (0%)	0/52 (0%)	0/52 (0%)	0/52 (0%)	2/52 (4%)	1/52 (2%)	5/52 (10%)	16/52 (31%)	0/52 (0%)

The denominator of 54 includes those who had "No Response." There were 5/54 (9%) and 16/54 (30%) "No Response" for 6000 and 8000 Hz, respectively. "No Response" for 6000 and 8000 Hz would not affect PTA

The mean PTA change at the 4-month from the baseline was 27 dB (SD=11). There were 52 out of 54 subjects who had PTA change greater than 10 dB, two subjects within  $\pm$  10 dB, and no subject below 10 dB.

#### QuickSIN

The objective was to demonstrate that the Esteem System at the 4-months postactivation visit is as effective as or better than the hearing aid for improving speech discrimination (intelligibility) as shown by the QuickSIN (speech in noise) test results.

The change with the Esteem® System from the aided baseline was  $-1 \pm 1$  at 4month and  $0 \pm 0$  at 10-month follow-up. The QuickSIN Test Manual quantifies the amount of SNR Loss (in dB) in relation to the degree (category) of SNR loss. Based on the cutoff values specified in QuickSIN Test Manual, the distributions of SNR Loss for the baseline aided and unaided conditions as well as for the 4and 10-month intervals are provided in Table XX. The distributions of SNR loss at baseline aided condition and at the 4 and 10 month visits were comparable.

SNR Löss	Degree of SNR Loss	Baseline Unaided (N=57) <sup>a</sup>	Baseline Aided (N≡57),	4 Month (N=54)	10 Month (N=52)
0-3 dB	Normal/near normal	2 (4%)	1 (2%)	1 (2%)	1 (2%)
>3-7 dB	Mild	12 (21%)	10 (18%)	8 (15%)	10 (19%)
>7-15 dB	Moderate	19 (33%)	29 (51%)	24 (44%)	29 (56%)
>15 dB	Severe	24 (42%)	17 (30%)	20 (37%)	12 (23%)

#### Table XX. QuickSIN SNR Loss Distributions.

#### APHAB Quality of Life (QOL)

The objective was to show that the Esteem® System improves Quality-of-Life when compared to the baseline aided condition as shown by APHAB scores (time period not specified in the clinical protocol). The mean benefit scores over the unaided condition were collected for the pre-implant baseline aided condition and at the 4- and 10-month intervals as shown in Table XXI. The APHAB score is broken down into sub-categories of Easy Communication Situations (EC), Background Noise Situations (BN), Reverberate Environments (RV) and Aversiveness (AV).

As shown in Table XXI, there was a mean increase of 10.9 (standard deviation = 17.9) in benefit score (APHAB) at 4-month comparing to the baseline (preimplant aided condition). The mean change in the four subscales ranged from 8.4 to 13.5, with the Easy Communication Situations (EC) subscale having the largest increase and the Reverberate Environment (RV) subscale having the smallest increase.

Table XXI. APHAB Mean	Benefit Score	(mean +/- standard error).

	Global Score mean ± se n (95% CI)	Mar - Selfs	7. EC Scale 3. mean ± se 3. n (95% CI) = 3	BN Scale mean ± se n (95% CI)	RV Scale 22 mean ± se n (95% CI)	AV Scale mean ± sē n (95% CI)
Baseline	18.7±1.7		38.9±2.9	29.8±2.2	34.7±2.6	-28.9±2.9
Aided	59 (15.4, 22.0)		59 (33.1, 44.7)	59 (25.4, 34.3)	59 (29.6, 39.9)	59 (-34.8, -23.0)
Esteem	28.3±2.5		50.5±3.1	39.5±3.3	42.0±3.5	-19.0±3.8
4-Month	53 (23.3, 33.3)		53 (44.3, 56.7)	53 (32.8, 46.2)	53 (35.0, 49.0)	53 (-26.6, -11.4)
Mean Difference in Benefit Score	10.9±2.5 53 (5.9, 15.8)	all the set	13.5±3.2 53 (7.1, 20.0)	10.2±3.1 53 (4.1, 16.3)	8.4±3.1 53 (2.1, 14.6)	11.4±4.0 53 (3.3, 19.5)
	间的" <b>太</b> "的					
Esteem	26.3±2.8		48.1±3.4	36.0±3.6	38.5±3.9	-17.9±3.9
10-Month	51 (20.7, 31.8)		51 (41.2, 55.0)	51 (28.7, 43.3)	51 (30.6, 46.4)	51 (-25.7, -10.2)
Mean Difference in Benefit Score	8.9±2.6 51 (3.8, 14.1)		11.4±3.4 51 (4.5, 18.3)	7.1±3.2 51 (0.7, 13.4)	5.0±3.1 51 (-1.3, 11.3)	12.2±4.0 51 (4.1, 20.2)

Table XXII provides the individual subject APHAB scores in percentage steps for Esteem at 4-months and 10-months follow-up compared to pre-implant baseline aided condition. The number and percent of subjects meeting each comparison step are provided for each APHAB score.

ĺ

page 41

		4 Month A	PHAB Comparis	on Results	
			N=53		
the second states of the se	Total	EC > 2	- <b>BN</b> _:	RV	AV X
% Better HA > +22%	13/53 (25%)	15/53 (28%)	18/53 (34%)	14/53 (26%)	17/53 (32%)
% Better HA +10 to 21%	14/53 (26%)	12/53 (23%)	10/53 (19%)	9/53 (17%)	11/53 (21%)
% Better HA +5 to 9%	5/53 (9%)	10/53 (19%)	4/53 (8%)	5/53 (9%)	4/53 (8%)
% Equal HA (±4%)	11/53 (21%)	6/53 (11%)	7/53 (13%)	9/53 (17%)	9/53 (17%)
% Below HA -5 to -9%	3/53 (6%)	1/53 (2%)	7/53 (13%)	6/53 (11%)	1/53 (2%)
% Below HA -10 to -21%	4/53 (8%)	6/53 (11%)	4/53 (8%)	8/53 (15%)	4/53 (8%)
<u>% Below HA ≤ -22%</u>	3/53 (6%)	3/53 (6%)	3/53 (6%)	2/53 (4%)	7/53 (13%)
H STATISTICS AND	Nu we amend	10 Month A	DUAD	DANKE -	
			N≡51		
	🕈 😰 Total 🍼 🚭	A REAL PROPERTY OF A CARACTERISTIC	S BNC CR	RV	AV
% Better HA > +22%	9/51 (18%)	13/51 (25%)	13/51 (25%)	11/51 (22%)	16/51 (31%)
% Better HA +10 to 21%	16/51 (31%)	16/51 (31%)	10/51 (20%)	13/51 (25%)	11/51 (22%)
% Better HA +5 to 9%	7/51 (14%)	6/51 (12%)	3/51 (6%)	1/51 (2%)	3/51 (6%)
% Equal HA (±4%)	8/51 (16%)	8/51 (16%)	10/51 (20%)	8/51 (16%)	7/51 (14%)
% Below HA -5 to -9%	6/51 (12%)	3/51 (6%)	5/51 (10%)	5/51 (10%)	5/51 (10%)
% Below HA -10 to -21%	2/51 (4%)	3/51 (6%)	6/51 (12%)	9/51 (18%)	7/51 (14%)
% Below HA < -22%	3/51 (6%)	2/51 (4%)	4/51 (8%)	4/51 (8%)	2/51 (4%)

#### Table XXII. APHAB Comparison by Subject.

As for the individual benefit comparison, according to the *Instructions for Manual* Scoring of the APHAB, a significant benefit has occurred if a difference of  $\geq 22\%$ is obtained for the EC, RV or BN score. If all three scores improve by  $\geq 10\%$ , there is a 96% probability that a true benefit has occurred. If all three scores improve by  $\geq 5\%$ , there is an 89% probability that a true benefit has occurred. Scoring of the benefit scores for the baseline aided condition and the Esteem at 4 and 10-month follow-up was calculated versus baseline unaided condition. In addition, the Esteem at the 4 and 10-month evaluation was compared to the baseline aided condition for each subject according to these same criteria. The number of subjects meeting each of the above scoring criteria is presented in Table XXIII.

There were 25 subjects (47%) at 4-month follow-up and 21 subjects (41%) at 10month follow-up who had a greater than 22% improvement in EC, RV or BN. However, less than one in three showed 96% probability of a significant benefit according to the APHAB scoring guideline.

#### Table XXIII. APHAB – Benefit Categories.

Benèfit Categories.	Esteem.vs Hearing Aid n/N (%)	Esteem vs⊭, Hearing Aid n/N (%) ⊶
	4-Month	10-Month
Significant Benefit		
Subjects with a $\ge 22\%$ improvement in EC, RV, or BN	25/53 (47.2%)	21/51 (41.2%)
96% Probability of a Significant Benefit	16/53 (30.2%)	13/51 (25.5%)
Subjects with $a \ge 10\%$ improvement in EC, RV, and BN		
89% Probability of a Significant Benefit	22/52 (42 40/)	
Subjects with $a \ge 5\%$ improvement in EC, RV, and BN	23/53 (43.4%)	19/51 (37.3%)

#### Esteem Questionnaire Quality of Life (QOL)

ί.

The objective was to gather subject's feedback and comments on the use of the Esteem® System relative to the baseline aided condition as shown by the Esteem Questionnaire (time period not specified in the protocol). At the 4- and 10-month follow-up, subjects completed a questionnaire rating various subjective attributes concerning their experience with the Esteem® System as compared to the baseline aided condition. Ratings were on a scale of 1 to 5, where 1 is much worse, 2 is somewhat worse, 3 is about the same, 4 is somewhat better, and 5 is much better.

The questions and responses are provided in Table XXIV. Subject ratings are summarized below:

- Clarity of Sound: 78% somewhat or much better, 7% equal, 15% somewhat or much worse
- Ability to Understand Speech in Background Noise: 69% somewhat or much better, 13% equal, and 18% somewhat or much worse
- Natural Sounding Voices: 76% somewhat or much better, 11% equal, 13% somewhat or much worse
- Understanding Conversation: 72% somewhat or much better, 17% equal, 11% somewhat or much worse
- Activity Level: 85% somewhat or much better, 11% equal, 4% somewhat or much worse
- Feeling of Confidence: 84% somewhat or much better, 8% equal, 8% somewhat or much worse
- Benefit of Invisibility: 66% somewhat or much better, 17% equal, 17% somewhat or much worse

## Table XXIV. Esteem Questionnaire (Quality of Life).

		😤 4 Mo	onth Res	) onse	
Question	1 - 1	22	3.2	- 4 · · ·	5.5 %
How do you rate the clarity of the sound you hear with the Esteem	3/54	5/54	4/54	13/54	29/54
compared to your hearing aid?	(6%)	(9%)	(7%)	(24%)	(54%)
How do you rate your ability to understand speech in background	3/54	7/54	7/54	17/54	20/54
noise or street noise with the Esteem as compared to your hearing	(6%)	(13%)	(13%)	(31%)	(37%)
aid?		j.			
How natural sounding are voices and other sounds compared to	1/54	6/54	6/54	13/54	28/54
your hearing aid?	(2%)	(11%)	(11%)	(24%)	(52%)
How do you rate the benefit of the entire system being invisible to	9/54	0/54	9/54	12/54	24/54
the onlooker compared to your hearing aid?	(17%)	(0%)	(17%)	(22%)	(44%)
How well do you understand conversation with your Esteem even	3/54	3/54	9/54	18/54	21/54
when several people are talking compared to your hearing aid?	(6%)	(6%)	(17%)	(33%)	(39%)
How confident do you feel with the Esteem compared to your	2/53	2/53	4/53	13/53	32/53
hearing aid?	(4%)	(4%)	(8%)	(25%)	(60%)
Does the Esteem allow you to live a more active lifestyle?	1/54	1/54	<b>ó</b> /54	13/54	33/54
	(2%)	(2%)	(11%)	(24%)	(61%)
		10 M	nutli Resi	ionse	
Question	1	<b>走之</b> 了	333	<b>i</b> 4	
How do you rate the clarity of the sound you hear with the Esteem	3/52	5/52	3/52	7/52	34/52
compared to your hearing aid?	(6%)	(10%)	(6%)	(13%)	(65%)
How do you rate your ability to understand speech in background	5/52	3/52	7/52	14/52	23/52
noise or street noise with the Esteem as compared to your hearing	(10%)	(6%)	(13%)	(27%)	(44%)
aid?					
How natural sounding are voices and other sounds compared to	3/52	5/52	4/52	14/52	26/52
your hearing aid?	(6%)	(10%)	(8%)	(27%)	(50%)
How do you rate the benefit of the entire system being invisible to	5/52	0/52	11/52	15/52	21/52
the onlooker compared to your hearing aid?	(10%)	(0%)	(21%)	(29%)	(40%)
How well do you understand conversation with your Esteem even	3/52	4/52	10/52	12/52	23/52
when several people are talking compared to your hearing aid?	(6%)	(8%)	(19%)	(23%)	(44%)
How confident do you feel with the Esteem compared to your	4/52	3/52	3/52	12/52	30/52
hearing aid?	(8%)	(6%)	(6%)	(23%)	(58%)
Does the Esteem allow you to live a more active lifestyle?	1/52	3/52	3/52	10/52	35/52
	(2%)	(6%)	(6%)	(19%)	(67%)

## 3. <u>Subgroup Analyses</u>

ļ

Outcomes systematically stratified based on subjects' (a) age, (b) degree of hearing loss, (c) WRS, and (d) length of hearing aid use experience are shown in Table XXVI.

#### Table XXVI. Stratified Results.

				hange at onths	WRS Change at 4 months		
Stratification Factor	Strata	N	Mean±SE	P-value For Strata Differences	Mean±SE	P-value For Strata Differences	
Age	< 47 years	18.	6.4±3.4		16.9±7.9	·	
	47 - 60.3 years	18	13.1±3.4	0.242	25.2±8.1	0.708	
	> 60.3 years	18	12.5±2.2	-	23.0±5.8		
Baseline Hearing Loss	Mild	3	10.0±5.0		20.7±6.6		
Severity (PTA)	Moderate	41	11.2±2.1	0.843	19.8±4.1	0.659	
	Severe	10	8.5±4.2		29.8±15.2	· · ·	
Baseline unaided WRS (at	< 60%	10	15.0±5.3	1	22.4±8.5		
max)	60% - 80%	23	11.1±2.4	0.389	·28.4±7.1	0.300	
	> 80%	21	8.1±2.9		14.0±6.0		
Length of hearing aid	<8 years	18	10.6±2.3	•	17.6±4.1		
experience	8 – 16 years	18	14.4±3.8	0.232	29.8±7.3	0.399	
	>16 years	18	6.9±2.9		17.8±9.3		

For age and length of hearing aid experience, subjects were divided into three equal sized groups (i.e. tertiles). For WRS, the division into three groups was based on commonly used clinical cutoff values of 60% and 80%.

Results were consistent among subgroups of subjects. Subjects of each subgroup exhibited a benefit of the Esteem System over the pre-implant aided condition.

However, the number of subjects for the mild hearing loss subgroup is only three, which makes it difficult to interpret results for this subgroup. Subsequently the mild hearing loss indication was removed from the labeling.

Although not statistically significant, the study device was shown to be more effective for females than for males. Mean SRT at 4 months for females was 14.7 (SD=14.4) vs 8.4 (SD=12.0) for males. Mean WRS at 4 months for females was 31.7 (SD=27.1) vs. 16.3 (SD=31.4) for males.

#### Section X / Appendix 1. Safety Algorithm

1

1

*Background:* Bone conduction (BC) using forehead probe placement was the primary test for cochlear function stability. While forehead placement would minimize some of the test variability issues associated with the mastoid probe placement as detailed in IDE G000321, it is still possible that BC test-retest variability may result in test results outside the  $\pm 10$  dB limits due to equipment limitations and probe placement. As an improvement over the methods used in IDE G000321, the Safety Algorithm has been refined for use in this new clinical trial. In addition to bone conduction, the EnvoyGram function was used as an in-situ audiogram to directly stimulate the cochlea. This method would be more accurate and a better indicator of cochlear stability than the previous EnvoyGram tests where testing done at implant was used to predict future performance.

*The EnvoyGram IT:* In addition to the programmable parameters used to affect the incoming signal, the Sound Processor has an internal tone generator that can be accessed through the Esteem Programmer in a test mode called the EnvoyGram IT (EnvoyGram In-situ). In other words, the EnvoyGram IT is an in-situ audiogram utilizing the Driver to test cochlear function. When entering this test mode, the Sensor is deactivated. The Esteem Programmer software allows the audiologists to select a frequency in the range 250 to 4000 Hz and amplitude in the range 55 to 119 dB SPL. The Sound Processor synthesizes and delivers a pure tone signal to the Driver to induce known vibrations directly into the cochlea. There are twelve steps of amplitude. Each step provides a 4 - 6 dB increase over the previous step. The typical EnvoyGram IT levels are based on: (a) typical intact chain displacement of 40 nm at 100 dB for frequencies below 1 kHz (Validated per ASTM F 2504 and EMC 003798-001), (b) a typical Model 7502 Driver displacement in temporal bones of 88 nm/V (Validated per EMC 003798-001), and (c) a typical SP tone output for each volume and tone setting (Validated per EMC 003788-101 and EMC 003872-001).

Each patient's intact chain has a unique displacement profile. During implant of the Esteem, intact chain data is measured and recorded to provide a normalization factor for the EnvoyGram IT. Intra-operative data, ASTM F 2504, and temporal bone studies at Envoy (i.e. EMC 003798-001) all indicate that patient-to-patient variability of intact chain displacement is at least  $\pm 6$  dB. ASTM F 2504 cites a 95% confidence interval of  $\pm 6$  dB in temporal bones. Clinical experience has also shown that accurately quantifying the intact chain displacement of each patient in a live surgical field is also limited to approximately  $\pm 6$  dB, due to presence of fluid in the middle ear space, available LDV laser angle, etc.

The EnvoyGram IT test protocol is similar to that of an audiogram. The intact-chain measurements are recorded on the Procedure and Discharge CRF (EMC 003900-003) and entered into the EnvoyGram IT by the audiologist. The test methodology is performed consistent with the Hughson-Westlake procedure. A signal is presented at the prescribed amplitude and frequency. If the subject acknowledges the signal, the intensity level is decreased two steps (10 - 12 dB). If that signal is not acknowledged, the intensity level is increased one step (6 dB), thus determining a threshold. This threshold provides a measure of cochlear function independent of the external auditory mechanism.

EnvoyGram IT SPL levels are customized to the patient by taking into account each patient's IC data. For instance, a patient with typical 40 nm IC displacement at 100 dB will have levels from 55 to 117 dB, but a patient with stiff 20 nm IC displacement at 100 dB will have levels from 61 to 123 dB. The table below lists the EnvoyGram levels for a) a typical intact chain displacement of 40 nm at 1.0 kHz, 100 dB SPL, b) an intact chain displacement of 20 nm at 1.0 kHz, 100 dB SPL, and c) an intact chain displacement of 80 nm at 1.0 kHz, 100 dB SPL. Table 1 displays the EnvoyGram IT levels in Esteem Programmer after intra-operative IC data entry. EnvoyGram IT levels are listed in dB SPL and are automatically calculated in the Esteem Programmer for each patient's IC data collected during implant procedure. These are the levels available for each of the test frequencies.

ŀ

(

(.

Typical (40nm IC @ 100dB SPL)		58	64	70	75	80	87	94	100	106	111	119
	1	64	70	76	81	86	93	100	106	112	117	125
Loose (80nm IC @ 100dB SPL)	49	52	58	64	69	74	81	88	94	100	105	113

Since the EnvoyGram IT levels are calibrated to each patient, the "predicted" EnvoyGram IT thresholds are equal to the baseline pre-implant unaided audiogram for each test frequency. For instance, a patient with 55 dB baseline air conduction threshold at 1 kHz and 80 nm measured IC would have a predicted EnvoyGram IT of 58 dB at 1 kHz (first level above baseline unaided threshold of 55 dB).


Safety Algorithm Explanation. The first level of the safety algorithm will use standard bone conduction (BC) thresholds. Bone conduction thresholds are measured in the implanted ear at 0.5, 1.0, 2.0, and 4.0 kHz at baseline and follow-up visits. If less than two of the follow-up thresholds are more than 10 dB greater than the baseline thresholds, then the individual test frequencies are evaluated. At each test frequency, if the follow-up threshold is less than 20 dB greater than the baseline threshold then the algorithm is considered complete, with a conclusion that cochlear change is improbable. However, if at least two of the thresholds have increased more than 10 dB or if any individual threshold has increased by 20 dB or more, then the EnvoyGram data is evaluated.

The second level of the safety algorithm will use EnvoyGram thresholds. Baseline unaided air conduction pure tone thresholds at 0.5, 1.0, 2.0, and 4.0 kHz are measured at baseline. Similarly, EnvoyGram thresholds are measured in the implanted ear at 0.5, 1.0, 2.0, and 4.0 kHz at follow-up visits. Based on the intra-operative intact chain data, an EnvoyGram equivalent dB threshold is calculated for each of the four test frequencies. If less than two of the follow-up EnvoyGram thresholds are more than 10 dB greater than the baseline thresholds, then the individual test frequencies are evaluated. At each test frequency, if the follow-up EnvoyGram threshold is less than 20 dB greater than the baseline threshold then the algorithm is considered complete, with a conclusion that cochlear change is improbable. However, if at least two of the EnvoyGram threshold has increased by 20 dB or more, then the algorithm is considered complete with a conclusion that cochlear change is probable.

For patients with moderate to severe sensorineural hearing loss, non-responses (NR) are not uncommon during bone-conduction testing. If an NR occurs during baseline bone conduction testing, that test frequency is not evaluated (for the same patient) in the follow-up bone conduction portion of the safety algorithm. However, if an NR occurs during follow-up bone conduction testing (and is not preceded by a baseline NR at the same test frequency), the corresponding EnvoyGram threshold change from baseline is substituted at the bone conduction NR test frequency.

#### Bone Conduction/Safety Algorithm

ļ



#### PMA P090018: FDA Summary of Safety and Effectiveness Data

53

## Section X / Appendix 2. Audiometric Data for Reconstructed Subjects

		Pre-Implant	Pre- Reconstruction	Reconstruction
	500 Hz	55	NR	45
	1000 Hz	45	NR	45
Air Conduction	2000 Hz	50	NR	50
	3- Frequency Average (dB HL)	50	NR	47
SRT	(in dB)	45	NR	45
WRS (inserts)	Maximum	92	NR	72
	500 Hz	50		45
	1000 Hz	40		45
Bone	2000 Hz	50		60
Conduction	3000 Hz	60		60
	4000 HZ	60		70
	3- Frequency Average (dB HL)	47		50
	500 Hz	5		0
	1000 Hz	5		0
Air-Bone Gap	2000 Hz	0		-10
	3- Frequency Average (dB HL)	3		-3

#### Subject 0203-103-17 JATST IDE G000321 Incudoplasty-2 Year Post Reconstruction

NR=No Response

(

1

(

#### Subject 0203-104-06 KAMHA IDE G000321 Incudoplasty-2 Months Post Reconstruction

ĺ

(

		Pre-Implant	Pre-	Reconstruction
	500 Hz	40	90	45
	1000 Hz	45	85	50
Air Conduction	2000 Hz	55	70	50
	3- Frequency Average (dB HL)	47	82	48
SRT	(in dB)	45	90	40
Speech Disc	Maximum	100	64	76
	500 Hz	45		35
	1000 Hz	50		45
Bone	2000 Hz	60		40
Conduction	3000 Hz	55		65
	4000 HZ	50		. 70
	3- Frequency Average (dB HL)	52		40
	500 Hz	-5		10
	1000 Hz	-5		5
Air-Bone Gap	2000 Hz	-5		10
	3- Frequency Average (dB HL)	-5		8

55

#### Subject 0203-102-05 KAGNI IDE G000321 PORP-9 Months Post Reconstruction

		Pre-Implant Unaided	Pré- Reconstruction	Reconstruction
	500 Hz	40	NA	60
	1000 Hz	50	NA	70
Air Conduction	2000 Hz	60	NA	65
	3- Frequency Average (dB HL)	50	NA	65
SRT	(in dB)	45	NA	60
Speech Disc	Maximum	92	NA	80
	500 Hz	30		55
	1000 Hz	40		65
Bone	2000 Hz	65		60
Conduction	3000 Hz	65		NA
	4000 HZ	65		80
	3- Frequency Average (dB HL)	44		60
	500 Hz	10		5
	1000 Hz	10		5
Air-Bone Gap	2000 Hz	5		5
	3- Frequency Average (dB HL)	1		5

NA = Not Available

ť

 $(\cdot$ 

To

#### Subject 0204-105-37 IDE G070162 Incudoplasty-12 Weeks Post Reconstruction

		Pre-Implant	Reconstruction	Post
	500 Hz	55	NA	60
	1000 Hz	60	NA	60
Air Conduction	2000 Hz	55	NA	55
	3- Frequency Average (dB HL)	57	NA	58
SRT	(in dB)	55	NA	60
WRS (inserts)	Maximum	100	NA	100
	500 Hz	40		40
	1000 Hz	55		40
Bone	2000 Hz	55	<b>在</b> 的日本中的14-50	45
Conduction	3000 Hz	65		55
	4000 HZ	65		75
	3- Frequency Average (dB HL)	50		42
	500 Hz	15		20
	1000 Hz	5		20
Air-Bone Gap	2000 Hz	0		10
	3- Frequency Average (dB HL)	7		16

NA=Not Available; Reconstruction was done at the same time as explant.

#### XI. <u>SUMMARY OF SUPPLEMENTAL CLINICAL INFORMATION</u>

The clinical information is discussed in Section X.

#### XII. PANEL MEETING RECOMMENDATION AND FDA'S POST-PANEL ACTION

#### A. Panel Meeting Recommendation

1

A meeting of the Ear, Nose, and Throat Devices Advisory Panel was held on December 18, 2009, to discuss and provide recommendations to FDA regarding the clinical data presented in the Pre-Market Approval Application (P090018) for the Esteem Totally Implantable Hearing System sponsored by Envoy Medical Corporation. The Esteem® is a totally implantable hearing device that is implanted in the middle ear to help hearing in adults with sensorineural hearing loss by replicating the ossicular chain and providing additional gain.

The Panel heard the company and FDA presentations, discussed the clinical data presented, addressed the FDA questions, and finally voted unanimously (15-0) to recommend that the PMA application for the Esteem Totally Implantable Hearing System

PMA P090018: FDA Summary of Safety and Effectiveness Data

57

sponsored by Envoy Medical Corporation be found "Approvable with Conditions." The proposed conditions included:

1) modification of the "Indications for Use" statement to specify only bilateral moderate to severe, sensorineural hearing loss;

2) patient speech intelligibility assessment must use recorded stimuli;

3) a minimum one-month trial with a hearing aid prior to acceptance for device implantation to ensure prior experience with traditional, acoustic hearing aid;

4) labeling should include performance results from the pivotal clinical trial, noting limitations of effectiveness data (Speech Reception Threshold, Word Recognition Score) compared to traditional acoustic hearing aid;

5) subject information should include reporting all adverse events;

6) a rigorous training and certification program must be completed by treating surgeons and audiologists prior to device usage; and

7) a post-approval study is necessary for following current subjects and to track new patients.

The webpage link to the P090018 panel transcript is found at: <u>http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/EarNoseandThroatDevicesPanel/ucm146740.htm</u>

#### B. FDA's Post-Panel Action

į

Both FDA and the applicant accepted all of the panel recommendations. Following the panel meeting, the applicant adequately revised the labeling to reflect all conditions of approval recommended by the panel. The applicant continued to work with FDA to adequately revise the post-approval study design in the 30 days following issuance of the approval order.

During the December 18, 2009 panel meeting, the panel members unanimously voted (15-0) in favor of a conditional approval for the Esteem® System. Conditions applicable to the safety of the device included:

1. Panel members recommended that "Normal Tympanic Membrane" to be added to the Indications for Use statement in addition Inclusion Criteria requirement.

2. Intense training would be provided to select group of surgeons (neuro-otologists) to overcome the site variability in the occurrence of adverse events.

3. 7% incidence of facial paresis/paralysis was a concern for all participants. Panel recommended better training of surgeons in proper surgical technique for the

Esteem Device placement to overcome this high incidence of facial nerve adverse event.

4. Improve labeling to accurately reflect the incidence of adverse events, revision rates, explantation rates, and extent of surgical procedures.

Subsequent to the ENT Advisory Panel recommendations, the applicant satisfactorily modified all pertinent documents to accurately reflect the incidence of revision surgeries, explantations, and facial nerve adverse events.

#### XIII. <u>CONCLUSIONS DRAWN FROM PRECLINICAL AND CLINICAL STUDIES</u>

#### A. <u>Safety Conclusions</u>

The adverse effects of the device are based on data collected in a clinical study conducted to support PMA approval as described above.

The primary safety objectives included: (a) incidence of serious adverse device effects (SADE), (b) incidence of device failures and replacements, (c) bone conduction (BC) threshold at 4 months post-activation vs. pre-implant, and (d) safety algorithm (SA) for those that fail BC. A summary of the results is shown below.

a. Incidence of SADEs:

- Three (3) subjects experienced facial weakness / incision issues.
- Three (3) subjects required revision procedures to date.
- The SADE rate was 10.5% (6 of 57).

In addition, major adverse event rates included:

- Taste Disturbance: 42% of patients (14% ongoing after 1 year).
- Facial Paresis/Paralysis: 7% of patients (1% ongoing after 1 year).
- Tinnitus: 18% (5% ongoing after 1 yr.)

b. Incidence device failures:

- Three (3) failures resulting in approved revisions were reported in three unique subjects prior to the 4-month follow-up.
- The failure rate was 5.3% (3 of 57).

c. Bone conduction threshold:

- Average 3 frequency (500, 1K, 2K) bone conduction change of 0.1 dB at 4 months vs. pre-implant.
- Average 3 frequency (500, 1K, 2K) bone conduction change of -0.8 dB at 10

PMA P090018: FDA Summary of Safety and Effectiveness Data

page 54

months vs. pre-implant.

d. safety algorithm (SA) for those that fail BC

- Individually, no subjects (0) at 4 months had BC/SA change per the protocol criteria from pre-implant.
- Individually, one subject (1) at 10 months had BC/SA change per the protocol criteria from pre-implant at 4 kHz.

#### B. Effectiveness Conclusions

The primary effectiveness endpoints included: (a) Speech Reception Threshold (SRT) at 4 months post-activation vs. pre-implanted aided condition and (b) Word Recognition Score (WRS) at 4 months post-activation vs. pre-implanted aided condition (at 50 dB HL input condition).

a. Speech Reception Threshold (SRT):

- Average SRT improvement of 10.6 dB at 4 months compared to their baseline aided condition (95% confidence interval varied from 7.1 to 14.2). The heterogeneity in the treatment effect among sites is statistically significant (p-value < 0.01). Due to site variability, the range of mean improvement was 1.3-16.9 dB.</li>
- Average SRT improvement of 11.4 dB at 10 months compared to their baseline aided condition.

b. Word Recognition Score (WRS):

At 4 months:

• Average WRS improvement at 4 months was 21.7 (95% Confidence Interval: 13.3 to 30.1).

• WRS was the same or better in 93% and worse in 7% of subjects as compared to hearing aids.

There is statistically significant heterogeneity in WRS among the sites (p-value = 0.01).

- 7% scored less than their pre-implant hearing aid (0%-20% depending upon clinical site),
- 37% scored equal to their pre-implant hearing aid (17%-53% depending upon clinical site), and
- 56% scored better than their pre-implant hearing aid (27%-83% depending upon clinical site).

PMA P090018: FDA Summary of Safety and Effectiveness Data

page 55

At 10 months:

- Average WRS improvement at 10 months was 19.8 (95% confidence interval: 11.1 to 28.4).
- WRS was the same or better in 88% and worse in 12% of subjects as compared to hearing aids.

Regarding the primary effectiveness data summarized above, the panel recommended that the applicant can claim that the Esteem can perform as well as hearing aids. However, the panel recommended disallowing any labeling claims that the Esteem is superior to hearing aids.

#### C. Overall Conclusions

The data in this application support the reasonable assurance of safety and effectiveness of this device when used in accordance with the indications for use.

The panel voted unanimously (15-0) for approval with conditions. These conditions were adequately addressed by the sponsor prior to issuance of the approval order.

#### XIV. CDRH DECISION

í

FDA issued an approval order on March 17, 2010.

The final conditions of approval cited in the approval order are described below.

1. Extended Follow-up of Premarket Cohort Study: Per agreement dated January 27, 2010 (e-mail) this study will address the following question: What is the long-term (5 years) safety and effectiveness of the Esteem device? This question will be addressed by extending the follow-up of the PMA pivotal clinical trial, which was designed as a prospective, multi-center non-randomized, 1-arm clinical trial to evaluate the safety and effectiveness of the Esteem® device. For this trial the subject acts as his or her own control. A total of 61 out of 62 patients were enrolled in the PMA pivotal clinical trial and followed out to one year. The continued access expansion study will follow these subjects out to 5-year follow-up. The study endpoints include: speech reception threshold (SRT) and word recognition score (WRS) for effectiveness; and safety endpoints include all adverse events at each follow up visit. The study protocol will include specific statistical hypotheses for the effectiveness endpoint at 5-years.

2. *The New Enrollment Study*: Per agreement dated January 27, 2010 (e-mail) this study will address the following questions: What is the long-term (5 years) safety and effectiveness of the Esteem device? Is the incidence of facial pareses/paralyses greater than 7% at 1-month? These questions will be addressed in a prospective, multi-center, non-randomized, audiologist-blinded, 1-arm observational study. For this study the subject acts as his or her own control. A total of 120 newly enrolled patients treated by newly trained surgeons at up to 10 investigational sites; consecutively treated patients

PMA P090018: FDA Summary of Safety and Effectiveness Data

page 56

GI

will be invited to participate in this post-approval study. The study participants will be followed for 5-years. Study endpoints for effectiveness include speech reception threshold (SRT) and word recognition score (WRS). Study endpoints for safety include all adverse events at each follow up visit. A safety hypothesis will be performed at 1-month (facial paresis/paralysis). An effectiveness hypothesis will be performed at 5 years.

The applicant's manufacturing facilities were inspected and found to be in compliance with the device Quality System (QS) regulation (21 CFR 820).

#### XV. APPROVAL SPECIFICATIONS

{ ·

Directions for use: See device labeling.

Hazards to Health from Use of the Device: See Indications, Contraindications, Warnings, Precautions, and Adverse Events in the device labeling. Post-approval Requirements and Restrictions: See approval order.

Ġơ